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A B S T R A C T
Background
Tonic-clonic convulsions and convulsive status epilepticus (currently defined as a tonic-clonic convulsion lasting at least 30 minutes) are
medical emergencies and require urgent and appropriate anticonvulsant treatment. International consensus is that an anticonvulsant
drug should be administered for any tonic-clonic convulsion that has been continuing for at least five minutes. Benzodiazepines
(diazepam, lorazepam, midazolam) are traditionally regarded as first-line drugs and phenobarbital, phenytoin and paraldehyde as
second-line drugs. This is an update of a Cochrane Review first published in 2002 and updated in 2008.
Objectives
To evaluate the effectiveness and safety of anticonvulsant drugs used to treat any acute tonic-clonic convulsion of any duration, including
established convulsive (tonic-clonic) status epilepticus in children who present to a hospital or emergency medical department.
Search methods
For the latest update we searched the Cochrane Epilepsy Group’s Specialised Register (23 May 2017), the Cochrane Central Register
of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 23 May 2017), MEDLINE (Ovid, 1946 to 23
May 2017), ClinicalTrials.gov (23 May 2017), and the WHO International Clinical Trials Registry Platform (ICTRP, 23 May 2017).
Selection criteria
Randomised and quasi-randomised trials comparing any anticonvulsant drugs used for the treatment of an acute tonic-clonic convulsion
including convulsive status epilepticus in children.
Data collection and analysis
Two review authors independently assessed trials for inclusion and extracted data.We contacted study authors for additional information.
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Main results
The review includes 18 randomised trials involving 2199 participants, and a range of drug treatment options, doses and routes of
administration (rectal, buccal, nasal, intramuscular and intravenous). The studies vary by design, setting and population, both in terms
of their ages and also in their clinical situation. We have made many comparisons of drugs and of routes of administration of drugs in
this review; our key findings are as follows:
(1) This review provides only low- to very low-quality evidence comparing buccal midazolam with rectal diazepam for the treatment
of acute tonic-clonic convulsions (risk ratio (RR) for seizure cessation 1.25, 95% confidence interval (CI) 1.13 to 1.38; 4 trials; 690
children). However, there is uncertainty about the effect and therefore insufficient evidence to support its use. There were no included
studies which compare intranasal and buccal midazolam.
(2) Buccal and intranasal anticonvulsants were shown to lead to similar rates of seizure cessation as intravenous anticonvulsants, e.g.
intranasal lorazepam appears to be as effective as intravenous lorazepam (RR 0.96, 95% CI 0.82 to 1.13; 1 trial; 141 children; high-
quality evidence) and intranasal midazolam was equivalent to intravenous diazepam (RR 0.98, 95% CI 0.91 to 1.06; 2 trials; 122
children; moderate-quality evidence).
(3) Intramuscular midazolam also showed a similar rate of seizure cessation to intravenous diazepam (RR 0.97, 95% CI 0.87 to 1.09;
2 trials; 105 children; low-quality evidence).
(4) For intravenous routes of administration, lorazepam appears to be as effective as diazepam in stopping acute tonic clonic convulsions:
RR 1.04, 95% CI 0.94 to 1.16; 3 trials; 414 children; low-quality evidence. Furthermore, we found no statistically significant or
clinically important differences between intravenous midazolam and diazepam (RR for seizure cessation 1.08, 95% CI 0.97 to 1.21; 1
trial; 80 children; moderate-quality evidence) or intravenous midazolam and lorazepam (RR for seizure cessation 0.98, 95% CI 0.91 to
1.04; 1 trial; 80 children; moderate-quality evidence). In general, intravenously-administered anticonvulsants led to more rapid seizure
cessation but this was usually compromised by the time taken to establish intravenous access.
(5)There is limited evidence froma single trial to suggest that intranasal lorazepammaybemore effective than intramuscular paraldehyde
in stopping acute tonic-clonic convulsions (RR 1.22, 95% CI 0.99 to 1.52; 160 children; moderate-quality evidence).
(6) Adverse side effects were observed and reported very infrequently in the included studies. Respiratory depression was the most
common and most clinically relevant side effect and, where reported, the frequency of this adverse event was observed in 0% to up
to 18% of children. None of the studies individually demonstrated any difference in the rates of respiratory depression between the
different anticonvulsants or their different routes of administration; but when pooled, three studies (439 children) provided moderate-
quality evidence that lorazepam was significantly associated with fewer occurrences of respiratory depression than diazepam (RR 0.72,
95% CI 0.55 to 0.93).
Much of the evidence provided in this review is of mostly moderate to high quality. However, the quality of the evidence provided for
some important outcomes is low to very low, particularly for comparisons of non-intravenous routes of drug administration. Low- to
very low-quality evidence was provided where limited data and imprecise results were available for analysis, methodological inadequacies
were present in some studies which may have introduced bias into the results, study settings were not applicable to wider clinical
practice, and where inconsistency was present in some pooled analyses.
Authors’ conclusions
We have not identified any new high-quality evidence on the efficacy or safety of an anticonvulsant in stopping an acute tonic-clonic
convulsion that would inform clinical practice. There appears to be a very low risk of adverse events, specifically respiratory depression.
Intravenous lorazepam and diazepam appear to be associated with similar rates of seizure cessation and respiratory depression. Although
intravenous lorazepam and intravenous diazepam lead to more rapid seizure cessation, the time taken to obtain intravenous access may
undermine this effect. In the absence of intravenous access, buccal midazolam or rectal diazepam are therefore acceptable first-line
anticonvulsants for the treatment of an acute tonic-clonic convulsion that has lasted at least five minutes. There is no evidence provided
by this review to support the use of intranasal midazolam or lorazepam as alternatives to buccal midazolam or rectal diazepam.
P L A I N L A N G U A G E S U M M A R Y
Drug management for acute tonic-clonic convulsions (fits), including convulsive status epilepticus in children
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Review question
This review aimed to assess whether the use of different anticonvulsant drugs, given by different routes of administration, have an impact
on how quickly an acute tonic-clonic-convulsion (fit) can be stopped. The review also investigated whether different anticonvulsant
drugs were accompanied by less frequent or different serious side effects.
Background
Tonic-clonic convulsions and convulsive status epilepticus are medical emergencies. In children, the first anticonvulsant drug is usually
given in the Accident and Emergency (A&E) Department of a hospital. This drug may be administered in a number of ways, including
into a vein (intravenously), into the mouth and between the cheeks (buccally), into the nostrils (intranasally) or into the rectum
(rectally). The first-choice drug should be effective, work rapidly and not be associated with any serious adverse effects. Research is
important to try and find the most effective and the safest anticonvulsant drug in this clinical situation.
Study characteristics
We carried out a review of all available and relevant evidence on the effectiveness and safety of anticonvulsant drugs used in the first-
line treatment of tonic-clonic convulsions in children who attended hospital A&E departments. This review examined data from 18
randomised controlled trials (RCTs); RCTs provide the most reliable evidence. They investigated the use of different anticonvulsant
drugs and given by different routes.
Key Results
The review included 18 RCTs involving 2199 children, and investigated many different anticonvulsant drugs, doses of the drugs and
routes of administration of the drugs. The studies also had some differences in their designs, their settings and the populations of
children included, in terms of their ages and their clinical situation (such as how long their convulsion had been going on when they
were recruited into the trial).
Analysis of two trials found no clear evidence of a different effect between intravenous lorazepam and intravenous diazepam in stopping
a tonic-clonic convulsion taken to an Emergency Department. There is uncertainty about whether buccal midazolam is more effective
than rectal diazepam as the first management of a tonic-clonic convulsion or convulsive status epilepticus when intravenous access
is unavailable. There is no good evidence that the intranasal route is as effective as the intravenous route. Consequently there is no
evidence that it can be used as an alternative route of administration.
Although medications such as midazolam, lorazepam and paraldehyde can reduce breathing rates, this is not a common complication
and was not seen very often in the included studies. Rates of serious side effects of these medications are generally very low.
Quality of the evidence
Many of the trials used different drugs, different dosages and different routes of administration. This has to be taken into account
when looking at the overall conclusion of this review. Most of the trials took place in large children’s hospitals or in large children’s
departments in a general hospital. This means that the results found in this review are probably relevant for similar clinical situations
throughout the world.
The quality of the evidence provided in this review ranged from very low to high. The quality of the evidence provided for some
outcomes is low to very low, due to imprecise results where limited information was available for analysis. There were also variability and
problems within the designs of some studies, which may have influenced the findings. The quality of evidence was lower in some study
settings which were specific to the country in which they were conducted, so the results may not reflect clinical practice worldwide.
The evidence is current to May 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lorazepam compared with diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Lorazepam
Comparison: Diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Diazepam Lorazepam
Seizure cessation
Follow-up: up to 24
hours
708 per 1000 765 per 1000
(694 to 850)
RR 1.08
(0.98 to 1.20)
439
(3 trials)
⊕⊕©©
low1,2
In two trials, drugs
were administered in-
travenously. In a third
trial, drugs were admin-
istered intravenously or
rectally if intravenous
access was not possi-
ble
Sub-
group analysis showed
a signif icant dif f erence
by route of interven-
t ion (intravenous: RR 1.
04 (95% CI 0.94 to 1.
16) compared to rec-
tally RR: 2.86 (95%CI 1.
47 to 5.55), test of sub-
groups P = 0.003)
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Time from drug admin-
istration to termination
of seizures
Follow-up: up to 24
hours
The mean time to ces-
sat ion of seizures was
84.94 seconds in the di-
azepam group
The mean time to ces-
sat ion of seizures was
6.18 faster (7.83 slower
to 20.19 faster) in the
lorazepam group
NA 80
(1 trial)
⊕⊕⊕©
moderate3
Drugs were adminis-
tered intravenously
Another trial (where
drugs were admin-
istered intravenously
or rectally) reported
sim ilar mean times
to seizure cessa-
t ion. Standard devia-
t ions were not available
so data could not be en-
tered into analysis
Incidence of respira-
tory depression
Follow-up: up to 24
hours
356 per 1000 256 per 1000
(196 to 331)
RR 0.72
(0.55 to 0.93)
439
(3 trials)
⊕⊕⊕©
moderate1
In two trials, drugs
were administered in-
travenously. In a third
trial, drugs were admin-
istered intravenously or
rectally if intravenous
access was not possi-
ble
There was no dif -
ference between the
routes of intervent ion
(test of subgroups, P =
0.86)
Additional drugs re-
quired to terminate
the seizure: addit ional
dose of study drug
Follow-up: up to 24
hours
305 per 1000 268 per 1000
(195 to 366)
RR 0.88
(0.64 to 1.20)
439
(3 trials)
⊕⊕©©
low1,2
In two trials, drugs
were administered in-
travenously. In a third
trial, drugs were admin-
istered intravenously or
rectally if intravenous
access was not possi-
ble
Subgroup analysis by
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route of intervent ion
(intravenous: RR 0.97
(95% CI 0.71 to 1.33)
compared to rectally
RR: 0.11 (95%CI 0.01 to
1.56), test of subgroups
P = 0.11)
Two trials also reported
whether addit ional
(other) ant iepilept ic
drugs were required to
stop the seizure. There
were no signif icant dif -
ferences overall or by
route of intervent ion
Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
266 per 1000 229 per 1000
(162 to 319)
RR 0.86
(0.61 to 1.20)
439
(3 trials)
⊕⊕⊕©
moderate1
In two trials, drugs
were administered in-
travenously. In a third
trial, drugs were admin-
istered intravenously or
rectally if intravenous
access was not possi-
ble
There was no dif -
ference between the
routes of intervent ion
(test of subgroups, P =
0.27)
Incidence of admis-
sions to the ICU
Follow-up: up to 24
hours
116 per 1000 17 per 1000
(2 to 114)
RR 0.15
(0.02 to 0.98)
86
(1 trial)
⊕⊕©©
low1,4
In the included trial,
drugs were adminis-
tered intravenously or
rectally if intravenous
access was not possi-
ble
There was no dif -
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f erence between the
routes of intervent ion
(test of subgroups P =
0.32)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: one included study was quasi-randomised, which may have led to select ion bias and
an intent ion-to-treat approach was not used in the study.
2Downgraded once due to inconsistency: a high proport ion of heterogeneity was present in the analysis, probably due to
dif ferences in the route of administrat ion and dif ferences in def init ion of ’seizure cessat ion’.
3Downgraded once due to imprecision: wide conf idence intervals around the ef fect size,
4Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to zero events in the intervent ion
group).
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B A C K G R O U N D
This review is an update of a previously published review in
the Cochrane Database of Systematic Reviews (Issue 3, 2008;
Appleton 2008).
Description of the condition
Convulsive status epilepticus (CSE) is a medical and neurologi-
cal emergency and if under- or inappropriately treated may result
in death or significant morbidity. Convulsive status epilepticus is
defined as more than 30 minutes of either continuous seizure ac-
tivity or two or more sequential seizures without full recovery of
consciousness between seizures (Glauser 2016). The 30-minute
definition is based on the duration of convulsive status epilepticus
that may lead to irreversible neuronal injury. Since most seizures
are brief, and once a seizure lasts more than five minutes it is likely
to be prolonged (Shinnar 2001), status treatment protocols are
based on a five-minute definition to minimise both the risk of
seizures reaching 30 minutes and potential adverse outcomes asso-
ciated with treating brief, self-resolving tonic-clonic convulsions.
It is generally believed that the longer the episode of CSE, the
more difficult it is to stop.
When the exact time of onset or duration of the convulsion is not
known, any person presenting to the A&E department in an acute
tonic-clonic convulsion tends to be managed according to the def-
inition of status epilepticus, with the primary objective of stop-
ping the convulsion, irrespective of its duration. Most published
national and international guidance, including from the National
Institute of Health and Care Excellence (NICE) in the UK (NICE
2012), the International League Against Epilepsy (ILAE) (Trinka
2015) and the American Epilepsy Society (AES) (Glauser 2016),
recommend treating a tonic-clonic seizure after five minutes. This
is because in over 90% of cases a tonic-clonic seizure will end
spontaneously within four minutes; it is assumed and likely that
a seizure that has continued for more than four minutes will not
stop spontaneously.
Description of the intervention
Twenty-five years ago, the first drug used to treat an acute tonic-
clonic convulsion in children was usually administered in the A&
E department (Garr 1999). However it is now more common that
parents/carers of children with either prolonged or recurrent (se-
rial) convulsions are prescribed ‘rescue’ medications, such as rectal
diazepam or buccal/intranasal midazolam to administer at home
(or even at school). An epidemiological study published in 2008
demonstrated that 61%of episodes of convulsive status epilepticus
in children were treated with pre-hospital emergency medication
and predominantly rectal diazepam (Chin 2008). Over-treatment
may be as potentially damaging as under-treatment by causing
respiratory depression/arrest (with a risk of consequent cerebral
hypoxia) or a potentially fatal cardiac arrhythmia.
How the intervention might work
Convulsive status epilepticus is a medical and neurological emer-
gency that may result in death or significant morbidity. The in-
tended aim of the intervention is to stop the acute tonic-clonic
seizure as rapidly as possible, without causing serious and poten-
tially life-threatening adverse side effects, and avoiding the need
for a second-line treatment.
Why it is important to do this review
This is an update of a Cochrane Review first published in 2002,
and updated in 2008. Since the last update (Appleton 2008), there
have been a number of newly-published randomised controlled
trials in children. These data contribute to the growing evidence
base on the management of acute tonic-clonic convulsions in chil-
dren. We therefore consider it appropriate to update the review.
O B J E C T I V E S
To evaluate the effectiveness and safety of the anticonvulsant drugs
used to treat any acute tonic-clonic convulsion of any duration,
including established convulsive (tonic-clonic) status epilepticus
in children presenting to a hospital or emergency medical depart-
ment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials of a parallel
design, blinded or unblinded.
Cluster-randomised and cross-over trials are not suitable designs
for the review, due to the nature of the condition and the treatment.
Types of participants
Children aged between one month and 16 years, presenting to an
A&E department or to a hospital ward (direct from the commu-
nity) in an acute tonic-clonic convulsion and who received treat-
ment with an anticonvulsant drug, irrespective of the duration of
the presenting convulsion.
8Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Children included those presenting with a first convulsion and
those with an established diagnosis of epilepsy. Any and all causes
of the convulsion (including convulsive status epilepticus) were
included in the review. We included studies where 70% or more of
the study population had generalised tonic-clonic seizures (GTC)
or secondarily generalised seizures, or where subgroup data for
children with GTC were available.
Types of interventions
In children presenting with an acute tonic-clonic seizure including
status epilepticus, we included trials if they compared two or more
treatments or two or more treatment protocols of the same anti-
convulsant. We included studies comparing first-line treatments
only (i.e. the first treatment a child received at the hospital). Stud-
ies of second-line treatments (e.g. the second treatment given at
hospital after a first seizure treatment had failed) were not within
the scope of this review. Specific drugs considered within this re-
view included the benzodiazepines (diazepam, lorazepam and mi-
dazolam), phenytoin, and paraldehyde. Different routes of drug
administration were also analysed where possible, including intra-
venous (IV), intranasal, buccal, rectal and intramuscular adminis-
tration. We consider different routes of drug administration sep-
arately in analyses.
Types of outcome measures
Primary outcomes
1. Presenting convulsion/episode of convulsive status epilepticus
stopped with the drug(s) used.
2. Time taken from administration of any drug in the hospital to
stopping of the convulsion.
3. The incidence of specific adverse effects: respiratory depression/
arrest; cardiac arrhythmia; hypotension and extravasation of any
intravenously-administered anticonvulsant
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion.
2. Recurrence of convulsions within 24 hours from stopping of
the presenting convulsion.
3. Incidence of admissions to the intensive care unit (ICU).
Search methods for identification of studies
We ran searches for the original review in 2002 and again in 2003,
2005, 2007, 2010, 2011, 2012, 2013, 2014, and 2017. For this
update we searched the following databases:
1. Cochrane Epilepsy Group Specialised Register (23 May
2017) using the search strategy outlined in Appendix 1;
2. The Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO, 23 May 2017), using the search strategy outlined in
Appendix 2;
3. MEDLINE (Ovid, 1946 to 23 May 2017) using the
strategy outlined in Appendix 3;
4. ClinicalTrials.gov (23 May 2017) using the strategy
outlined in Appendix 4;
5. WHO International Clinical Trials Registry Platform
(ICTRP, 23 May 2017) using the strategy outlined in Appendix
5.
There were no language restrictions.
Data collection and analysis
Selection of studies
Two review authors (AmyMcTague and Richard Appleton) inde-
pendently assessed trials for inclusion. We first screened titles and
abstracts, followed by full-text reports of potentially eligible trials,
resolving any disagreements by discussion.
Data extraction and management
All three review authors (Amy McTague, Richard Appleton and
Tim Martland) independently extracted the outcome data speci-
fied above, as well as the following data. We resolved any disagree-
ments by discussion.
Methodological/trial design
1. Method of randomisation.
2. Method of double-blinding.
3. Whether any participants had been excluded from the
reported analyses.
Participant/demographic information
1. Total number of participants allocated to each treatment
group/audited in any protocol.
2. Age/sex.
3. Number and type of background anti-epileptic drugs.
4. Whether any pre-hospital emergency anticonvulsant
treatment was given.
5. Duration of presenting tonic-clonic seizure/episode of
convulsive status.
6. Cause of acute tonic-clonic seizure/episode of convulsive
status.
Assessment of risk of bias in included studies
Two review authors (Amy McTague and Richard Appleton) in-
dependently assessed the risks of bias in the included studies, us-
ing the Cochrane ’Risk of bias’ tool (Higgins 2011b). We judged
whether each study was at high, low or unclear risk of bias in each
of the following domains:
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1. Random sequence generation;
2. Allocation concealment;
3. Blinding;
4. Incomplete outcome data;
5. Selective outcome reporting.
6. Other potential risks of bias.
We resolved any disagreements by discussion.
Measures of treatment effect
Dichotomous outcomes (e.g. number of childrenwith convulsions
stopped, number of children with specific adverse events, etc.)
were expressed as risk ratios (RRs) with 95% confidence intervals
(CIs). Continuous outcomes (e.g. time to stop the seizure/status
episode) were expressed as mean differences (MDs) with 95%CIs.
Unit of analysis issues
We did not anticipate unit-of-analysis issues, as the unit of allo-
cation and analysis must be the individual for all included trials,
and cross-over designs would not be suitable for this review, given
the acute nature of the convulsions.
The participant was the preferred unit of analysis, but where re-
sults were reported in terms of ’episodes’ (i.e. the same child being
treated for multiple seizures in the same trial), where participant-
specific information could not be extracted we accepted episode-
level information. This is a limitation, as meta-analysis assumes
independence between measurements, and more than one treated
seizure per child would not be statistically independent. A conse-
quence of ignoring this unit-of-analysis issue could be over-opti-
mistic confidence intervals.
Where we included studies with multiple treatment arms, multi-
ple treatment doses or different routes of administration, we con-
sidered each eligible treatment, dose or route of intervention in
separate comparisons.
Dealing with missing data
The analyses conducted in this review aimed to take an ’intention-
to-treat’ approach where possible, i.e. including all randomised
participants, analysed in the treatment group to which they were
allocated, irrespective of which treatment they actually received.
Where data were missing, we attempted to contact the study au-
thors for this information. If we could not acquire the missing
data, we conducted a ’complete-case’ analysis and took account of
the limitations of this approach when interpreting results.
Assessment of heterogeneity
We assessed clinical heterogeneity by reviewing the differences
across trials in characteristics of recruited participants and treat-
ment protocols. We also estimated heterogeneity statistically using
a Chi2 test for heterogeneity and the I2 statistic. We interpreted
the I2 statistic as follows (Higgins 2011a):
• might not be important (I2 values 0% to 40%);
• may represent moderate heterogeneity (I2 values 30% to
60%);
• may represent substantial heterogeneity (I2 values 50% to
90%); and
• considerable heterogeneity (I2 values 75% to 100%).
Assessment of reporting biases
To assess selective reporting bias, we compared the measurements
and outcomes planned by the original iInvestigators during the
trial with those reported within the published paper, by checking
the trial protocols (when available) against the information in the
final publication. Where protocols were not available, we com-
pared the ’Methods’ and the ’Results’ sections of the published
papers. We also used our knowledge of the clinical background
to identify standard outcome measures usually taken, but not re-
ported by the trial investigators.
If a sufficient number of trials (10 or more) had been included
for any comparison, we would have investigated publication bias
using a funnel plot.
Data synthesis
We analysed data using the fixed-effect model in the first instance.
Where we found substantial or considerable heterogeneity, we re-
peated the analysis with a random-effects model.
Subgroup analysis and investigation of heterogeneity
Weassessed clinical and statistical heterogeneity using themethods
outlined in Assessment of heterogeneity.
If appropriate, we considered different measurement times of the
primary outcome (seizure cessation); i.e. if different trials reported
this outcome at different time points or if any trials reported this
outcome at multiple time points. In the former case, we also cal-
culated a pooled summary of the measurement time subgroups
and performed the Chi2 test for differences between subgroups.
In the latter case, where a trial reported multiple time points, we
reported subgroup results only and did not pool the results.
Sensitivity analysis
We planned a sensitivity analysis based on the methodological
quality of the studies. However, given the small number of studies
included in each comparison, we did not deem this sensitivity
analysis to be appropriate, but wewill consider a sensitivity analysis
based on study quality for future updates of the review.
Summary of Findings and Quality of the Evidence
(GRADE)
In a post hoc change in line with current Cochrane guidance, for
the 2017 update we added a ’Summary of findings’ table for each
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comparison presented in the review, reporting all of the primary
and secondary outcomes.
We determined the quality of the evidence using the GRADE ap-
proach (GRADEPro 2004), downgrading evidence in the pres-
ence of a high risk of bias in at least one study, indirectness of the
evidence, unexplained heterogeneity or inconsistency, imprecision
of results, or high probability of publication bias. We downgraded
evidence by one level if we considered the limitation to be serious,
and by two levels if very serious.
R E S U L T S
Description of studies
Results of the search
The original Cochrane Review (2002) identified a single study
(Appleton 1995).
The update in 2008 identified three further studies (Ahmad 2006;
Lahat 2000; McIntyre 2005).
For this update, we have identified 14 further studies that meet
the main inclusion criteria in addition to the single study in the
original review and the three studies identified for the 2008 up-
date. (Arya 2011; Ashrafi 2010; Baysun 2005; Chamberlain 1997;
Chamberlain 2014; Fi gin 2002; Gathwala 2012; Javadzadeh
2012; Mahmoudian 2004; Momen 2015; Mpimbaza 2008; Shah
2005; Sreenath 2010; Talukdar 2009).
Full details of searches conducted before 2012 are unavailable.
Figure 1 shows the study flow diagram for searches completed
between 2012 and 2017, in addition to the studies already listed
in the 2008 update of the review.
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Figure 1. Study flow diagram.
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Searches conducted been 2012 and 2017 identified 140 records,
including 41 duplicate records. We screened 99 records (title and
abstract) for inclusion in the review and excluded 65 clearly irrel-
evant records. With the four studies included in previous versions
of the review and two studies excluded from previous versions of
the review, we assessed 40 full-text articles or clinical trials reg-
istry entries. We excluded 20 studies (see Excluded studies) and
included 18 studies (reported in 20 full-text articles or clinical tri-
als registry entries) in the review.
Included studies
We included 18 trials in this review (Ahmad 2006; Appleton
1995; Arya 2011; Ashrafi 2010; Baysun 2005; Chamberlain 1997;
Chamberlain 2014; Fi gin 2002; Gathwala 2012; Javadzadeh
2012; Lahat 2000; Mahmoudian 2004; McIntyre 2005; Momen
2015; Mpimbaza 2008; Shah 2005; Sreenath 2010; Talukdar
2009). All were hospital-based studies.
This section gives a brief description of the characteristics and
participants of each included trial; see Characteristics of included
studies for further details.
Ahmad 2006 was a 12-month, open, randomised study compar-
ing intranasal lorazepam (0.1mg (100 micrograms)/kg) and intra-
muscular paraldehyde (0.2 mg (200 micrograms)/kg) as the first-
line treatment of children aged two months to 12 years, present-
ing to a paediatric emergency centre with a generalised convulsion
continuing for at least five minutes. The study was carried out in
Malawi, Africa. Intramuscular paraldehyde is commonly used as
a first-line treatment for acute tonic-clonic seizures in sub-Saha-
ran Africa but is associated with injury around the injection site,
sterile abscesses and is incompatible with plastics. Patient demo-
graphics were similar in each group. Because of the geographical
location of this study most of the children had acute symptomatic
seizures, mainly due to acute brain infection (cerebral malaria or
bacterial meningitis in two-thirds of each of the two study groups).
Randomisation was allocated in advance by computer in blocks
of 10; after identification and treatment of children with hypo-
glycaemic seizures, investigators opened an unmarked envelope
which contained details of treatment allocation. Primary outcome
was the clinical cessation of the seizure within 10 minutes of drug
administration. Children with features of hepatic or hypertensive
encephalopathy or organophosphate poisoning were excluded, as
were children who had received an anticonvulsant agent within
one hour of presentation. For children in whom clinical seizure
activity continued after 10 minutes, investigators followed a lo-
cally-agreed protocol. The study evaluated 160 children of both
sexes.
Appleton 1995 was a one-year open, quasi-randomised study,
comparing lorazepam and diazepam, with the drugs given either
intravenously or rectally depending on ease of venous access. This
study evaluated 102 children, aged between one month and 16
years, of both sexes, presenting with an acute tonic-clonic convul-
sion including established convulsive status epilepticus to an A&
E department of a large children’s hospital. The study accepted all
causes of the convulsion or status, including symptomatic and id-
iopathic. No child had evidence of acute head trauma, metabolic
encephalopathy, bacterial meningitis or herpes simplex encephali-
tis as a cause of their presenting convulsion. No children were in-
cluded with known pseudo-tonic-clonic convulsions or pseudo-
convulsive, absence or complex partial status. The demography
of the two treatment groups was very similar (age; sex; numbers
with pre-existing epilepsy; numbers with a pre-existing neurolog-
ical disorder and duration of the presenting convulsion prior to
treatment with the two study drugs). Cessation of the seizure was
defined as the seizure or episode of status stopping within seven
or eight minutes of administration of the first dose of the study
anticonvulsant. If the presenting convulsion had not stopped by
eight minutes, then a second dose of either lorazepam or diazepam
would be given. If this seizure persisted, then an additional anti-
convulsant would be given, based on the hospital’s protocol for
managing convulsive status epilepticus (Garr 1999).
Arya 2011 was a randomised controlled trial comparing intranasal
and intravenous (IV) lorazepam for the treatment of convulsive
status epilepticus in children. The trial took place in the emer-
gency room of a hospital in New Delhi, India. Inclusion criteria
were children aged six to 14 years who presented convulsing or
who developed a seizure during the emergency room attendance.
Exclusion criteria were receipt of any anti-epileptic drug (AED)
within one hour of enrolment, the presence of severe cardiovascu-
lar compromise, and the presence of cerebrospinal fluid (CSF) rhi-
norrhoea or upper respiratory infection severe enough to prevent
intranasal administration. Fifty-eight children (41%) had GTC,
77 (54%) had partial seizures and six were described as having
“others/unclear”. The groups were evenlymatched for age, gender,
seizure type and prior AED administration. The primary outcome
measure was cessation of visible motor activity by 10 minutes.
Secondary outcome measures were persistent cessation of seizure
activity at one hour, time to IV access, time from drug administra-
tion to stopping of the seizure and development of hypotension/
respiratory depression. Further seizures were treated with intra-
venous phenytoin.
Ashrafi 2010 was a randomised controlled trial conducted in
two large hospitals in Tehran, Iran, comparing buccal midazolam
and rectal diazepam for the control of acute convulsive seizures.
Ninety-eight children aged more than three months with an acute
prolonged seizure lasting more than five minutes and those con-
vulsing while attending the emergency rooms were enrolled, irre-
spective of the cause of the seizure. Patients who already had in-
travenous access or who were younger than three months were ex-
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cluded. Most (84 patients or 86%) had GTC, with the remainder
being myoclonic, focal clonic and focal tonic seizures. There was
no significant difference between the two groups for age, sex or
seizure type. Randomisation was by a random-number table to ei-
ther buccal midazolam (0.3 to 0.5 mg/kg) or rectal diazepam (0.5
mg/kg). The primary outcome measure was cessation of all motor
activity in less than five minutes, without respiratory depression
and without another seizure. Further seizures were treated with in-
travenous diazepam. The outcome measures were further defined
as treatment initiation time and drug effect time. The authors also
examined the convenience of drug use and parental acceptance of
the drug/route of administration for each group.
Baysun 2005 was a prospective randomised study of all children at-
tending the emergency roomof a children’s hospital inTurkeywith
a seizure, regardless of type, aetiology and whether the seizure was
prolonged (this was assumed). No exclusion criteria were stated.
Forty-three children ranging in age from two months to 12 years
were recruited and randomised to buccal midazolam (0.25 mg/
kg) on even days of the month and rectal diazepam (0.5 mg/kg
for under-fives and 0.3 mg/kg for those aged six or more) on odd
days of the month. The two groups did not differ significantly by
sex, age, type of seizures or anti-epileptic drug used. Ten children
in the midazolam group and 10 in the diazepam group had GTC.
The remaining participants presented with generalised tonic, sim-
ple partial and complex partial seizures. Outcome measures were
cessation of convulsive seizure activity within 10 minutes, time to
response, and need for a second drug. Those who did not respond
within 10 minutes were given the alternative drug, i.e. midazolam
given to those who had already received diazepam and vice versa.
Chamberlain 1997 was a prospective, open randomised study of
the management of children aged 0 to 18 years presenting to the
emergency department of two large hospitals in the USA, with
motor seizures of at least 10 minutes’ duration (all had tonic-
clonic or clonic seizures - clarified in personal communication).
The study compared intramuscular midazolam (0.2 mg/kg) with
intravenous diazepam (0.3 mg/kg). Children who had established
intravenous access or who had already received treatment for this
seizure episode were excluded. Primary outcome measures were
seizure cessationwithin fiveminutes of administration, seizure ces-
sationbetweenfive and10minutes after administration (defined as
delayed seizure control), and treatment failure (lack of cessation by
10 minutes). Those who had treatment failure were subsequently
given intravenous diazepam or phenytoin. Other outcome mea-
sures included recurrence of seizures, defined as early recurrence
if within 15 minutes, or recurrence if within 60 minutes. Twenty-
eight children were identified for enrolment, but three were ex-
cluded as their seizures did not persist beyond 10 minutes. One
child who was randomised to diazepam was a protocol violation
due to failure to establish intravenous access, necessitating treat-
ment with intramuscular midazolam. Twenty-three children with
24 seizure episodes were studied (one child had two episodes and
appears in the study twice, once in each group). The demographics
were similar between the two groups.
Chamberlain 2014 was a large multicentre randomised controlled
trial conducted in the emergency departments of 11North Ameri-
can hospitals, comparing intravenous lorazepam with intravenous
diazepam for convulsive status epilepticus in children. Inclusion
criteria were children aged three months to 18 years with gener-
alised tonic-clonic status epilepticus. This was defined as three or
more seizures in the previous hour, two or more successive seizures
with no recovery of consciousness with an ongoing seizure, or an
ongoing seizure lasting at least fiveminutes. Children who had ini-
tial focal seizures rapidly evolving to bilaterally convulsive seizures
were included. Patients with the following factors were excluded:
known pregnancy, significant cardiac arrhythmia, urgent need for
surgical intervention and anaesthesia, known contraindication to
benzodiazepines or benzodiazepine use in the previous seven days
(including pre-hospital use by ambulance personnel). “Early ter-
minators” were children removed from the study following ad-
ministration of the study drug due to discovery of an exclusion
factor or a refusal to participate by the family. The study assessed
11,630 patients for eligibility, of whom 11,320 were excluded,
mainly because they were not having an acute seizure or did not
meet the inclusion criteria. The study randomised 310 children
to one of the two study drugs. Twenty-two and 15 children were
early terminators from each treatment arm respectively, and were
excluded from the efficacy analysis. Further exclusions largely due
to protocol deviations resulted in 102 and 107 children being
available for per protocol analysis in each treatment arm. The par-
ticipants in each treatment arm were well-matched in demograph-
ics and seizure aetiology. Primary efficacy outcome measures were
cessation of status epilepticus (defined as cessation of generalised
convulsive activity with return of consciousness within the four-
hour observation period) within 10 minutes of the initial dose,
and seizure freedom for 30 minutes. Secondary outcome measures
included latency of drug response (time to cessation of convul-
sions), need for a dose of study medication, need for further anti-
convulsants and sustained seizure freedom for 60minutes and four
hours. Primary safety outcomes were severe respiratory depression
(needing assisted ventilation) within four hours of the study drug
administration; secondary safety outcomes were aspiration pneu-
monia, any degree of respiratory depression, time required to re-
turn to baseline mental status, and degree of sedation or agitation
as measured by the Riker Sedation-Agitation scale.
Fi gin 2002 was a prospective, randomised, single-centre study of
children aged between one month and 13 years, presenting with
an acute seizure to the emergency room of a children’s hospital in
Turkey. All children who were seizing on arrival were included, as
it was presumed that their seizure had been ongoing for at least
five minutes.No exclusion criteria are stated and the aetiology of
the seizures is not given. Of 45 enrolled in the study, 28 children
(14 per treatment group) had generalised tonic-clonic seizures,
the rest presenting with simple focal (10), secondarily generalised
(4), tonic (1) and myoclonic (2) seizures. Both febrile and afebrile
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seizures were included, although only 10% of the participants had
a febrile seizure, and were equally distributed between the two
groups. Children were randomised on alternate days to rectal di-
azepam (0.3mg/kg) or nasal midazolam (0.2mg/kg). If the seizure
continued beyond 10 minutes, the alternative drug was given, i.e.
there was cross-over between the two groups. Persistent convul-
sions (not clearly defined) were treated with intravenous midazo-
lam by bolus, then infusion. Outcome measures were stopping of
the seizure within 10 minutes, response time, and necessity for a
second drug. There was no significant difference between the two
groups for age or seizure type.
Gathwala 2012 was a randomised controlled trial undertaken in an
Indian teaching hospital, comparing intravenous diazepam, mida-
zolam and lorazepam for the treatment of acute convulsive seizures
in children. Children aged six months to 14 years presenting with
a convulsion to the emergency department were recruited. Chil-
dren with liver or renal disease, cardiovascular abnormalities, head
injury, diabetes mellitus or hypoglycaemia were excluded, as were
those whose seizure had already stopped or where intravenous ac-
cess could not be established. The study assessed 185 children for
inclusion, of whom 65 were excluded; 55 did not meet the inclu-
sion criteria, seven declined, and intravenous access could not be
established in three. Participants were randomised into three treat-
ment groups, which were evenlymatched for demographics, mean
duration of seizure, prolonged seizures, those presenting with first
episode, and cause of seizure. The primary outcome measure was
time to seizure cessation, defined as cessation of visible epileptic
phenomena or return of purposeful response to external stimuli
within 15 minutes of drug administration. The secondary out-
comes were the effects of the drugs, i.e. vomiting, apnoea, som-
nolence, respiratory depression and requirement for mechanical
ventilation. Other secondary outcomes were the number of par-
ticipants with seizure recurrence, requirement for a second dose
of medication, uncontrolled seizures, and the time to seizure re-
currence.
Javadzadeh 2012 was a randomised unblinded study of 60 chil-
dren aged between two months and 15 years, presenting to the
emergency department with an acute seizure. Exclusion criteria
were patients with prior IV access, previous anticonvulsant treat-
ment, or concurrent respiratory tract infection. Participants were
randomised to intranasal midazolam or intravenous diazepam, al-
though all patients were cannulated on arrival. Outcomemeasures
included time needed to control seizure, oxygen saturations, and
heart rate pre- and post-treatment.
Lahat 2000 was a 12-month single-centre randomised study com-
paring intranasal midazolam (0.2 mg/kg) and intravenous di-
azepam (0.3 mg/kg) in the treatment of prolonged febrile seizures
(a seizure of at least 10 minutes duration) in children aged six
months to five years. The study was carried out in a paediatric
emergency department within a general hospital. Patient demo-
graphics were similar in both groups. Treatment was successful if
the clinical features of the seizure stopped within five minutes.
If the seizure stopped at between five and 10 minutes, this was
identified as a delayed but successful treatment. Treatment failures
(continued seizure activity after 10 minutes) received intravenous
diazepam and then phenobarbital in accordance with local guide-
lines. Randomisation was allocated in advance by a random-num-
ber table, with investigators receiving an opaque envelope with
each allocation at the time of administration. Forty-four children
of both sexes were evaluated, with a total of 52 seizure episodes.
Children who had received an anticonvulsant or had an intra-
venous line sited by paramedics prior to hospital attendance were
excluded from the study.
Mahmoudian 2004 is a prospective randomised study of children
aged two months to 15 years, presenting with an acute seizure
to the paediatric emergency department of a general hospital in
Iran over a two-month period. Seventy children who presented
with an acute seizure (length not specified) were randomised by an
odd- and even-number table to receive 0.2 mg/kg of intravenous
diazepam or 0.2 mg/kg of intranasal midazolam. Fifty children
presented with GTC, six with simple partial seizures, twelve with
complex partial seizures and five with myoclonic seizures (note
that multiple seizure types can occur in a single child). Outcome
measures were time from treatment to cessation of seizure, with
treatment considered successful if the seizure stopped within 10
minutes. Seizures that did not stopwithin 10minutes were defined
as treatment failures. Treatment failures in the midazolam group
were given intravenous diazepam and those in the diazepam group
were given intravenous phenobarbitone. Aetiologies of the seizures
were reported, andwere not evenly distributed between the groups;
14 of the midazolam group versus one of the diazepam group had
febrile convulsions, and 10 of the diazepam group versus four in
themidazolam group had central nervous system (CNS) infection.
McIntyre 2005 was a 40-month, multicentre, randomised, con-
trolled trial comparing buccal midazolam (approximately 0.5 mg/
kg) with rectal diazepam (0.5 mg/kg) as the first-line treatment
of children aged six months to 15 years, presenting to a paedi-
atric A&E department with active seizures.The primary outcome
measure was clinical cessation of the seizure within 10 minutes of
drug administration, without seizure recurrence within one hour
and without respiratory depression. Children with partial seizures
or non-convulsive status epilepticus were excluded from the trial.
Weekly blocks of treatment of either buccal midazolam or rectal
diazepam were randomly selected in each of the four participating
centres. Participant demographics were similar between groups.
Locally-agreed guidelines were followed in the event of continued
seizure activity after the 10-minute period. The study evaluated
219 seizure episodes in 177 children of both sexes. Separate re-
sults were reported both for total episodes and for first presenting
episodes, to minimise potential bias of children with multiple en-
tries. In contrast with the other studies included in the previous
review, children were not excluded if they had received anticon-
vulsant agents prior to their attendance at the A&E department.
Momen 2015 was an unblinded randomised trial of 100 children
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aged one month to 16 years. Inclusion criteria were children older
than one month who were convulsing on arrival. The length of
the ongoing seizure was not taken into account, so children with
relatively short-lived seizure may have been included. Exclusion
criteria were established IV access, prior administration of rectal
or nasal benzodiazepines, lack of consent or serial seizures with no
recovery of consciousness. In addition, a history of serious adverse
reactions to either of the study medications was an exclusion cri-
terion. Participants were randomised to intramuscular midazolam
or rectal diazepam. The main outcome measure was seizure cessa-
tion without recurrence within 60 minutes. Respiratory rate and
blood pressure were also monitored.
Mpimbaza 2008 was a single-blinded, placebo-controlled ran-
domised clinical trial in a paediatric emergency unit in Kampala,
Uganda. The inclusion criteria were children aged three months
to 12 years who presented while convulsing or who experienced a
seizure that lasted more than five minutes while in the unit, and
who had no documented evidence of having received intravenous
diazepam or phenobarbitone in the 24 hours before presentation.
Children aged less than three months or more than 12 years, who
had evidence of prior treatment or whose convulsion stopped prior
to treatment, were excluded. The study recruited 330 participants
(note that multiple seizure types can occur in a single participant):
269 (82%) had generalised tonic-clonic seizures, 18 had tonic
seizures, 61 had focal seizures and three had myoclonic seizures.
Participants were randomised by a random-number table to 0.5
mg/kg of rectal diazepam or buccal midazolam. A placebo which
was identical in volume and similar in colour was simultaneously
given with the study drug. The participants were well-balanced by
age, sex, and type of seizure between the two groups. The primary
outcome measure was cessation of visible seizure activity within
10 minutes, without recurrence in the subsequent hour. If the
convulsion lasted longer than 10 minutes or recurred within one
hour, this was considered a treatment failure and the child was
given intravenous diazepam. Secondary outcome measures were
the proportion with cessation of convulsions within 10 minutes,
the proportion with recurrence in the next hour and within 24
hours of initial control, and time to recurrence within these peri-
ods.
Shah 2005 was a prospective controlled quasi-randomised study
of the treatment of acute seizures in children in a tertiary general
hospital in Mumbai, India, including children presenting to the
emergency department and thosewhowere already admitted to the
ward or intensive care unit (ICU). The study enrolled 115 children
with an acute seizure (definition unclear) over a one-year period
in a single centre. Those who had already had treatment for the
seizure were excluded. Participants who already had intravenous
accesswere treatedwith 0.2mg/kg of intravenous diazepam.Those
without were randomised to treatment with 0.2 mg/kg of intra-
muscular midazolam or to the establishment of intravenous access
and treatment with intravenous diazepam. Sixty-three children
had generalised tonic-clonic seizures, and were equally divided be-
tween the two treatment groups. Of the remaining participants,
47 had focal, four had tonic and one had clonic seizures. Outcome
measures were mean time to cessation of seizures and the presence
of adverse effects. Those who did not respond after five minutes
were treated with other “anticonvulsants” (not specified).
Sreenath 2010 was a randomised controlled study of the man-
agement of convulsive status epilepticus (defined as continuous
convulsive activity lasting for five minutes or more) in children
presenting to a single centre in North India. Exclusion criteria
were treatment with any anti-epileptic medication in the preced-
ing four weeks, acute head trauma, history of poisoning and jaun-
dice, suspected renal failure, or diarrhoea presenting with seizures.
The study randomised 178 children aged one to 12 years by com-
puter-generated table to receive lorazepam 0.1 mg/kg or diazepam
0.2 mg/kg. If intravenous access was not present, the drug was
given rectally at the same dose. If the seizures recurred within
an undefined time frame, a second dose of the same drug was
given. The diazepam group were given a loading dose of 18 mg/
kg of phenytoin after 15 to 30 minutes, regardless of whether the
seizure had recurred. Sixty-three per cent had generalised tonic-
clonic seizures, while the rest were tonic (10%), clonic (10%),
myoclonic (0.5%), simple partial (2%), complex partial (10%),
and partial with secondary generalisation (4%). Themajority were
therefore generalised convulsive or motor seizures. The primary
outcome measure was cessation of seizure activity, with treatment
considered successful if this occurred within 10 minutes of the
first intervention and without recurrence over the next 18 hours.
Secondary outcomes were time taken for initial (presenting) con-
vulsion to stop after administration of the first drug, the num-
ber of doses of study drug required to treat the initial convulsion,
the use of an additional anti-epileptic drug, the total number of
seizures occurring in the first 18 hours following administration
of the study drug, the development of respiratory depression, the
number of participants requiring transfer to ICU for mechanical
ventilation, and the number of participants requiring cross-over
to an alternative regimen (i.e. from diazepam to lorazepam and
vice versa).
Talukdar 2009was a prospective randomised study of 120 children
who attended the paediatric emergency department of a Delhi
hospital with a seizure, the length of which was not defined. Those
with myoclonic, absence and atonic seizures were excluded. The
mean age of the participants was 3.2 years, with 73.3% under five
years of age and 53.3% under one year. Seventy-four per cent of
the children presented with GTC, while the rest were complex
partial or tonic seizures. The groups were not significantly differ-
ent in age, sex, seizure type or underlying aetiology. Participants
were allocated by a random-number table to 0.2 mg/kg of buccal
midazolam or 0.3 mg/kg of intravenous diazepam. The primary
outcome measure was cessation of all motor activity within or by
five minutes of administration of the drug. The drug response was
further analysed as treatment initiation time (time from noting
seizure to drug administration), drug effect time (time from drug
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administration to effect) and total controlling time, a combination
of the previous two.
Excluded studies
We excluded 20 studies from the review for the following reasons
(see Characteristics of excluded studies for further information):
• The study evaluated refractory status epilepticus (i.e.
children who have failed a first or second treatment for status
epilepticus) rather than acute status epilepticus (Agarwal 2007;
Arpita 2014; Mahmoudian 2006; Mehta 2007; Mittal 2014;
Rosati 2016; Singhi 2002).
• The study was not randomised or did not have a control
group, or both (Kutlu 2003; Morton 2007; Qureshi 2002).
• Fewer than 70% of included participants had GTCs (or it
was unclear how many participants had GTCs) (Bhattacharyya
2006; Scott 1999; Tonekaboni 2012).
• The study examined drug management for the long-term
prevention of recurring febrile seizures (Camfield 1980;
Heckmatt 1976; Strengell 2009) or clusters of seizures
(Cereghino 1998), rather than management of acute convulsions.
• The study was not conducted in a hospital setting (Holsti
2010; Silbergleit 2012).
• The study was published only as a conference abstract and
we could not contact the authors for additional information to
assess eligibility (McCormick 1999).
Risk of bias in included studies
The results of our ’Risk of bias’ evaluations are summarised in
Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Fourteen studies reported adequate methods for random sequence
generation (e.g. computer-generated randomisation, block ran-
domisation, etc.) and we judged them to be at low risk of bias.
Four studies (Appleton 1995; Baysun 2005; Fi gin 2002; Shah
2005) reported inadequate methods for random sequence genera-
tion and we judged these to be at high risk of bias. Three of these
studies (Appleton 1995; Baysun 2005; Fi gin 2002) used an alter-
nating (’odd’ and ’even’) day approach to randomisation and one
study (Shah 2005) was partially randomised, including patients
attending the emergency department and inpatients in the pae-
diatric ward or intensive care unit. Those who already had intra-
venous access were selected to receive intravenous diazepam, and
those without were further randomised to intramuscular midazo-
lam or intravenous diazepam. For those who were randomised, it
was unclear how randomisation was performed.
Regarding allocation concealment, nine studies described ade-
quate methods of concealment such as centralised allocation or
sealed opaque envelopes and we judged them to be at low risk
of bias. Six studies (Appleton 1995; Baysun 2005; Fi gin 2002;
McIntyre 2005; Momen 2015; Shah 2005) did not conceal al-
location and we judged them to be at high risk of bias. The re-
maining three studies did not mention allocation concealment
and we judged them to be at unclear risk of bias (Ashrafi 2010;
Chamberlain 1997; Talukdar 2009).
Blinding
One study was double-blinded (Chamberlain 2014) and one trial
had single-blinded participants (Mpimbaza 2008). The remaining
sixteen studies were unblinded, and for many of them blinding
would have been impractical, due to different routes of interven-
tion. However, given the objective nature of the main outcomes
of these studies (e.g. seizure cessation), it is unlikely that the lack
of blinding would affect results, so we rated all studies at low risk
of bias.
Incomplete outcome data
We judged 15 studies to be at low risk of bias, since all recruited
participants were included and analysed on an intention-to-treat
basis. We judged one study (Appleton 1995) to be at high risk of
bias. In this study there were a relatively large number of protocol
violators (16of 102 children, or 16%of the total study population)
and these violators were excluded from the analyses. The analysis
was therefore not an intention-to-treat analysis.
We judged two studies (Chamberlain 1997; Gathwala 2012) as
being at unclear risk of bias. In Chamberlain 1997, three chil-
dren who were randomised to receive diazepam were subsequently
excluded, as their seizures did not persist for 10 minutes. There
was also a protocol violator who was randomised to receive intra-
venous diazepam but received intramuscular midazolam after 25
minutes, due to unsuccessful intravenous access. This participant
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was excluded from the analysis and obviously would have skewed
the results significantly if he/she had been included. It may have
been helpful to know the response time of this child once treat-
ment was administered, as this is an important example of the
disadvantages of the intravenous route. In Gathwala 2012, three
children were excluded due to difficulties obtaining intravenous
access, and this may have introduced a source of bias. It could be
argued that the data cannot be considered to have been analysed
on an intention-to-treat basis, as these participants were excluded
from the analysis. However, given that all routes were intravenous
the effect of this is likely to have been small.
Selective reporting
Fourteen studies reported all expected and prespecified outcomes
andwe judged them tobe at low risk of bias.We rated two studies at
high risk of bias; Javadzadeh 2012 did not report seizure cessation,
which we would expect to be reported, and in Mahmoudian 2004
the authors did not report the time taken to insert intravenous
cannulae in the intravenous diazepam group. This would have
a significant effect on the time from arrival to seizure cessation.
Other studies that compared intravenous with other routes have
included this information.
We judged two studies to be at unclear risk of bias. Fi gin 2002
stated that information about previous convulsions and history of
anti-epileptic medication were collected according to the Meth-
ods but not reported in the Results section. It is unlikely that this
information influenced outcomes, but we are unclear why the in-
formation was not reported. Lahat 2000 defined seizure cessation
in the Methods section as “successful” if seizures stopped in less
than five minutes, “successful but delayed” if seizures stopped after
five to 10 minutes, and “failure” if seizures had not stopped after
10 minutes. However, results seem to be presented only in terms
of treatment success and failure. It is unclear if this is selective
reporting of results.
Other potential sources of bias
We identified additional high risks of bias in five studies. In two
studies, a high proportion of the children recruited had either
cerebral malaria ormeningitis, whichmay have impacted upon the
results (Ahmad 2006; Mpimbaza 2008). In Appleton 1995 there
was a large discrepancy in the two routes of administration used in
the study, probably due to clinician uncertainty about the use of
rectal lorazepam. This discrepancy is likely to have impacted upon
results. In Chamberlain 1997, one child was enrolled in the study
twice, and is represented in both groups.Due to the small numbers
of children included in the study, this double-enrolment may have
impacted on the results. In Gathwala 2012, the definition of the
’seizure cessation’ outcome used is different from all the other
included studies, and is not an appropriate criterion for judging
seizure cessation. This definition is likely to have impacted upon
results.
In four studies, it was unclear whether additional bias was present.
In three studies (Ashrafi 2010; Mahmoudian 2004; Sreenath
2010), one or both treatment arms showed a 100% seizure cessa-
tion rate, which is higher than expected. However, it was unclear
whether these unexpected results were due to a particular element
of the trial design. In Fi gin 2002, the description of the seizure
type and aetiology of participating children was unclear, so we
cannot be sure that the population of this study is generalisable.
We found no other biases in the remaining nine studies (Arya
2011; Baysun 2005; Chamberlain 2014; Javadzadeh 2012; Lahat
2000;McIntyre 2005;Momen 2015; Shah 2005; Talukdar 2009).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - Lorazepam compared with diazepam; Summary
of findings 2 Summary of findings - Intranasal lorazepam
compared with intramuscular paraldehyde; Summary of findings
3 Summary of findings - Intravenous lorazepam compared
with intravenous diazepam/intravenous phenytoin combination;
Summary of findings 4 Summary of findings - Intravenous
lorazepam compared with intranasal lorazepam; Summary of
findings 5 Summary of findings - Buccal midazolam compared
with rectal diazepam; Summary of findings 6 Summary
of findings - Buccal midazolam compared with intravenous
diazepam; Summary of findings 7 Summary of findings -
Intranasal midazolam compared with intravenous diazepam;
Summary of findings 8 Summary of findings - Intranasal
midazolam compared with rectal diazepam; Summary of findings
9 Summary of findings - Intramuscular midazolam compared
with intravenous diazepam; Summary of findings 10 Summary
of findings - Intramuscular midazolam compared with rectal
diazepam; Summary of findings 11 Summary of findings -
Intravenous midazolam compared with intravenous diazepam;
Summary of findings 12 Summary of findings - Intravenous
midazolam compared with intravenous lorazepam
In the 18 included trials, specific drugs (i.e. benzodiazepines (di-
azepam, lorazepam andmidazolam), phenytoin, and paraldehyde)
were compared to each other; different routes of drug administra-
tion (i.e. intravenous, intranasal, buccal, rectal and intramuscular)
of the same drug or different drugs were compared.
Considering the different drugs and different routes of adminis-
tration, this review makes 12 comparisons. The results of each
comparison are also summarised in ’Summary of findings’ tables:
Summary of findings for the main comparison: Lorazepam versus
diazepam;
Summary of findings 2: Intranasal lorazepam versus intramuscular
paraldehyde;
Summary of findings 3: Intravenous lorazepam versus intravenous
diazepam/intravenous phenytoin combination;
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Summary of findings 4: Intravenous lorazepam versus intranasal
lorazepam;
Summary of findings 5: Buccal midazolam versus rectal diazepam;
Summary of findings 6: Buccal midazolam versus intravenous di-
azepam;
Summary of findings 7: Intranasal midazolam versus intravenous
diazepam;
Summary of findings 8: Intranasal midazolam versus rectal di-
azepam;
Summary of findings 9: Intramuscular midazolam versus intra-
venous diazepam;
Summary of findings 10: Intramuscular midazolam versus rectal
diazepam;
Summary of findings 11: Intravenous midazolam versus intra-
venous diazepam;
Summary of findings 12: Intravenous midazolam versus intra-
venous lorazepam.
Table 1 also shows the study-specific event rates for the out-
comes ’Presenting convulsion/episode of convulsive status epilep-
ticus stopped with the drug(s) used,’ ’Incidence of respiratory de-
pression’ and ’The need to use additional anti-epileptic drugs to
stop the presenting convulsion’.
1. Lorazepam versus diazepam
Three trials recruiting 455 participants compared lorazepam to di-
azepam (Appleton 1995; Chamberlain 2014; Gathwala 2012). All
participants in Chamberlain 2014 and Gathwala 2012 received
drugs intravenously; inAppleton 1995, children received the drugs
either intravenously or rectally (where intravenous access was not
possible). As the route of administration in this trial was not ran-
domised, we test the route of administration for lorazepam and
diazepam by subgroup analyses rather than by separate compar-
isons.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used.
All three studies reported the number of children with their pre-
senting seizure(s) stopped by the trial drug. There was no statisti-
cally significant difference between the treatments when adminis-
tered intravenously; risk ratio (RR) 1.04, 95% confidence interval
(CI) 0.94 to 1.16, P = 0.43, Analysis 1.1. There was no hetero-
geneity present in this analysis (I2 = 0%).
For the 25 participants in Appleton 1995 who received the treat-
ments rectally, lorazepam was statistically significantly more effec-
tive for seizure cessation than diazepam; RR 2.86, 95% CI 1.47
to 5.55, P = 0.002, Analysis 1.1. We are cautious when interpret-
ing this result, due to the unbalanced number of children receiv-
ing each drug rectally (six received lorazepam and 19 received di-
azepam).
Overall, for both routes of administration, therewas no statistically
significant difference between the treatments; RR 1.08, 95% CI
0.98 to 1.20, P = 0.13, low-quality evidence, Analysis 1.1.We note
that this analysis has substantial heterogeneity (I2 = 67%), which
may be due to the differences in the results by the different routes
of administration (test for subgroup differences: Chi2 = 8.61, df
= 1, P = 0.003, I2 = 88.4%).
2. Time taken from administration of any drug in the
hospital to stopping the convulsion.
Gathwala 2012 reported that there was no significant difference
for time to seizure cessation, with a mean difference 6.18 seconds,
95% CI -7.83 to 20.19, P = 0.39, moderate-quality evidence,
Analysis 1.2.
Appleton 1995 reports the mean and range of times for the pre-
senting convulsion to stop is 29 seconds (range 25 to 60) for the
intravenous lorazepam, 26 seconds (range 20 to 51) for the in-
travenous diazepam group, 37 seconds (range 31 to 48) for the
rectal lorazepam group, and 38 seconds (range 35 to 49) for the
rectal diazepam group. Standard deviations were not available, so
we cannot enter data into analysis.
Chamberlain 2014 did not report on this outcome.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
All three studies reported the incidence of respiratory depression.
When administered intravenously, there were significantly fewer
occurrences of respiratory depression with lorazepam compared to
diazepam; RR 0.71, 95% CI 0.55 to 0.92, P = 0.01, 414 children,
Analysis 1.3. There was no heterogeneity present in this analysis
(I2 = 0%).
For the 25 participants in Appleton 1995 who received the treat-
ments rectally, there was no significant difference between treat-
ments; RR 0.95, 95% CI 0.04 to 20.78, P = 0.98, Analysis 1.3.
However, as above we are cautious when interpreting this result,
due to the unbalanced number of children receiving each drug
rectally.
Overall for both routes of administration, there were significantly
fewer occurrences of respiratory depression with lorazepam com-
pared to diazepam; RR 0.72, 95%CI 0.55 to 0.93, P = 0.01, mod-
erate-quality evidence, Analysis 1.3. There was no heterogeneity
present in this analysis (I2 = 0%) and no significant difference be-
tween the routes of administration (test for subgroup differences:
Chi2 = 0.03, df = 1, P = 0.86, I2 = 0%).
Gathwala 2012 reported that there was a significant increase
in somnolence between the diazepam and both the midazolam
21Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and lorazepam groups, but other adverse effects were evenly dis-
tributed. Chamberlain 2014 also reported that there was an in-
creased incidence of sedation in the lorazepam group (absolute
risk difference (ARD) 16.9%, 95% CI 6.1 to 27.7) and increased
time taken to return to baseline mental status in the lorazepam
group (hazard ratio (HR) 1.96, 95% CI 1.35 to 2.84, P < 0.001).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion.
All three studies reported the number of children requiring an
extra dose of trial medication to stop the presenting seizure. There
was no statistically significant difference between the treatments
when administered intravenously (RR 0.97, 95%CI 0.71 to 1.33,
P = 0.86, 414 children, Analysis 1.4), rectally (RR 0.11, 95% CI
0.01 to 1.56, P = 0.10, 25 children, Analysis 1.4) or for both routes
of administration (RR 0.88, 95% CI 0.64 to 1.20, P = 0.41, low-
quality evidence, Analysis 1.4). Some heterogeneity was present
in the combined analysis (I2 = 50%), which is probably due to
the differences in routes of administration, although the test for
subgroup differences did not reach statistical significance (test for
subgroup differences: Chi2 = 2.58, df = 1, P = 0.11, I2 = 61.3%).
Appleton 1995 and Chamberlain 2014 also reported the num-
ber of children requiring treatment with additional anti-epilep-
tic drugs to stop the presenting seizure. There was no statistically
significant difference between the treatments when administered
intravenously (RR 0.91, 95% CI 0.54 to 1.55, P = 0.73, 334 chil-
dren, Analysis 1.5), rectally (RR 0.11, 95% CI 0.01 to 1.69, P
= 0.11, 25 children, Analysis 1.5) or for both routes of adminis-
tration (RR 0.75, 95% CI 0.45 to 1.24, P = 0.26, 359 children,
Analysis 1.5). Some heterogeneity was present in the analysis com-
bining both routes of administration (I2 = 54%), which is proba-
bly due to the differences in routes of administration, although the
test for subgroup differences did not reach statistical significance
(test for subgroup differences: Chi2 = 2.20, df = 1, P = 0.14, I2 =
54.5%).
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion.
All three trials reported the number of children with recurrences of
seizures within 24 hours. There was no statistically significant dif-
ference between the treatments when administered intravenously
(RR 0.91, 95% CI 0.65 to 1.27, P = 0.56, 414 children, Analysis
1.6), rectally (RR 0.19, 95% CI 0.01 to 2.92, P = 0.23, 25 chil-
dren, Analysis 1.6) or for both routes of administration (RR 0.86,
95% CI 0.61 to 1.20, P = 0.36, moderate-quality evidence, 439
children, Analysis 1.6). There was no heterogeneity present in the
pooled analyses and no differences by route of administration were
found (test for subgroup differences: Chi2 = 1.23, df = 1, P = 0.27,
I2 = 19.0%).
3. Incidence of admissions to the intensive care unit (ICU)
Appleton 1995 reported the number of admissions to the ICU.
There was no statistically significant difference between the intra-
venously (RR 0.07, 95% CI 0.00 to 1.22, P = 0.07, 61 children,
Analysis 1.7), and rectally (RR 0.57, 95% CI 0.03 to 10.51, P =
0.71, 25 children, Analysis 1.7) separately. However, when com-
bining both routes of administration, significantly more children
who received diazepam were admitted to the ICU (10 compared
to 0 who received lorazepam) (RR 0.15, 95% CI 0.02 to 0.98, P =
0.05, low-quality evidence, 86 children, Analysis 1.7). There was
very little heterogeneity present in the pooled analysis and no dif-
ference by route of administration (test for subgroup differences:
Chi2 = 0.99, df = 1, P = 0.32, I2 = 0%).
2. Intranasal lorazepam versus intramuscular
paraldehyde
One trial (Ahmad 2006), recruiting 160 participants, compared
intranasal lorazepam to intramuscular paraldehyde.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus terminated with the drug(s) used
There was no statistically significant difference between the in-
tranasal lorazepamand intramuscular paraldehyde groups for stop-
ping the presenting seizure, with 60/80 (75%) in the intranasal
lorazepam group compared to 49/80 (61%) in the intramuscular
paraldehyde group: RR 1.22, 95% CI 0.99 to 1.52, P = 0.07,
moderate-quality evidence, Analysis 2.1.
2. Time taken from administration of any drug in the
hospital to stopping the convulsion
This outcome was not reported in the trial.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
There was no difference between the treatment groups for clini-
cally-important cardiorespiratory events (low-quality evidence).
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Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
Statistically significantly more children (8/80 (10%)) in the in-
tranasal lorazepam group required two or more additional anti-
convulsant doses to stop the seizures, compared to 21/80 children
(26%) in the intramuscular paraldehyde group: RR 0.38, 95% CI
0.18 to 0.81, P = 0.01, low-quality evidence, Analysis 2.2.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
There was no statistically significant difference between the treat-
ment groups for seizure recurrence within 24 hours: RR 0.73, 95%
CI 0.31 to 1.71, P = 0.47, low-quality evidence, Analysis 2.3.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
3. Intravenous lorazepam versus intravenous
diazepam/intravenous phenytoin combination
One trial (Sreenath 2010), recruiting 178 participants, com-
pared intravenous lorazepam to intravenous diazepam/intra-
venous phenytoin combination.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
There was no difference between intravenous lorazepam and in-
travenous diazepam-phenytoin combination for seizure cessation
within 10 minutes (100% in both groups: RR 1.00, 95% CI 0.98
to 1.02, P = 1.00, moderate-quality evidence, Analysis 3.1.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
There was no statistically significant difference in the median time
to seizure cessation (20 seconds in each group, moderate-quality
evidence).
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
Four participants in the intravenous lorazepam group experienced
respiratory depression, compared to five in the intravenous di-
azepam-phenytoin combination group. This difference was not
statistically significant: RR 0.78, 95% CI 0.22 to 2.82, P = 0.71,
moderate-quality evidence, Analysis 3.2.
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
No additional anti-epileptic drugs were required, as seizures
stopped in all children within 10minutes (Analysis 3.1). However,
only six participants in the intravenous lorazepam group required
more than one dose of the trial drug to stop the seizures, compared
to 14 in the intravenous diazepam-phenytoin combination group.
This difference was not statistically significant: RR 0.42, 95% CI
0.17 to 1.04, P = 0.06, moderate-quality evidence, Analysis 3.3.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
There were no seizure recurrences in either group (moderate-qual-
ity evidence). The authors suggest that the lack of recurrences in
the diazepam-phenytoin group may have been due to the addition
of phenytoin as a longer-acting drug.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
4. Intravenous lorazepam versus intranasal lorazepam
One trial (Arya 2011), recruiting 141 participants, compared in-
travenous lorazepam to intranasal lorazepam. Results are presented
for the subgroup of 58 participants with GTC.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
There were no statistically significant differences between intra-
venous and intranasal lorazepam for seizure cessation within 10
minutes: RR 1.07, 95% CI 0.77 to 1.49, P = 0.70, moderate-
quality evidence, or within one hour: RR 0.70, 95% CI 0.43 to
1.17, P = 0.17, Analysis 4.1.
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2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
Median time to achieve seizure control from drug administration
was four minutes in both groups (moderate-quality evidence).
The authors note that across all participants (including those with-
out GTC), the time taken to achieve intravenous access ranged
from one to 25minutes, with a median of four minutes. If this had
been included in the response time for the intravenous lorazepam,
the results would have been skewed significantly in favour of in-
tranasal lorazepam.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
Results were not available for the subgroup of participants with
GTC. Across all participants (including those without GTC), one
child from the intranasal group and two children from the intra-
venous group required respiratory support ( moderate-quality ev-
idence) No participant in either group demonstrated significant
hypotension.
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
This outcome was not reported in the trial.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
This outcome was not reported in the trial.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
5. Buccal midazolam versus rectal diazepam
Four trials, recruiting 648 participants, compared buccal mida-
zolam to rectal diazepam (Ashrafi 2010; Baysun 2005; McIntyre
2005; Mpimbaza 2008). One trial (177 participants; McIntyre
2005) reported on 219 seizure episodes; in other words, the same
child was randomised and treated for multiple seizures in the same
trial. Results are not available at the participant level so results
reported for McIntyre 2005 are by episode. This is a limitation, as
meta-analysis assumes independence between measurements, and
more than one treated seizure per child would not be statistically
independent. A result of ignoring this unit-of-analysis issue could
be overoptimistic confidence intervals.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
All four studies reported the number of children with their pre-
senting seizure(s) stopped by the trial drug. Buccal midazolam was
statistically significantly more effective than rectal diazepam for
seizure cessation: RR 1.25, 95% CI 1.13 to 1.38, P < 0.001, very
low-quality evidence, Analysis 5.1.
However, there was considerable heterogeneity in the analysis (I
2 = 81%). When we repeated the analysis with a random-effects
model, there was no statistically significant difference between the
treatments: RR 1.23, 95% CI 0.98 to 1.54, P = 0.08. The hetero-
geneity may be due to the four trials measuring seizure cessation
at different time points (Ashrafi 2010 five minutes; RR 1.22, 95%
CI 1.07 to 1.40, P = 0.004; Baysun 2005 and Mpimbaza 2008
10 minutes; RR 1.07, 95% CI 0.95 to 1.21, P = 0.26; McIntyre
2005 one hour; RR 2.05, 95% CI 1.45 to 2.91, P < 0.001). We
considered these different times in a subgroup analysis and found
a significant difference between the subgroups (test for subgroup
differences: Chi2 = 12.35, df = 2, P = 0.002, I2 = 83.8%, Analysis
5.1).
Seizure cessation data at one hour were also provided by the au-
thors ofMpimbaza 2008, showing that buccal midazolam was sig-
nificantly more effective than rectal diazepam: RR 1.42, 95% CI
1.06 to 1.90.
The doses of the drugs used in the studies were also different:
Baysun 2005 used 0.25 mg/kg for buccal midazolam, whereas
Mpimbaza 2008 and McIntyre 2005 used 0.5 mg/kg, and Ashrafi
2010 used 0.3 to 0.5 mg/kg. Furthermore, in Mpimbaza 2008
67.3%of the childrenhadmalaria and13.7%had cerebralmalaria;
when only children without malaria were analysed, buccal mida-
zolam was statistically significantly more effective than rectal di-
azepam for seizure cessation (RR 2.11, 95% CI 1.26 to 3.54; data
provided by the author). Furthermore, for the subgroup of chil-
dren with only GTC, 109/135 (80.7%) in the buccal midazolam
group compared to 97/134 (72.4%) in the rectal diazepam group
had seizure cessation; RR 1.12, 95% CI 0.98 to 1.27; data pro-
vided by the author.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
Baysun 2005 noted that there was no difference between groups
in the time from drug administration to seizure cessation, and
Ashrafi 2010 reported that both the median treatment initiation
time and drug effect time were significantly shorter in the buccal
midazolam group than in the rectal diazepam group (low-quality
evidence).
McIntyre 2005 andMpimbaza 2008 did not report this outcome.
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3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
All four studies reported on the incidence of respiratory depression.
Across the four trials, 25/346 in the buccal midazolam groups
and 26/344 in the rectal diazepam groups experienced respiratory
depression, but this difference was not statistically significant; RR
0.88, 95% 0.61 to 1.25, P = 0.47, low-quality evidence, Analysis
5.2.
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
McIntyre 2005 reported that fewer children in the buccal mida-
zolam group required intravenous lorazepam to stop the seizure
compared to the rectal diazepam group; RR 0.58, 95% CI 0.42 to
0.79, P < 0.001, low-quality evidence, Analysis 5.3. Baysun 2005
also noted no difference in the need for a second drug.
Ashrafi 2010 and Mpimbaza 2008 did not report this outcome.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
None of the trials reported this outcome.
3. Incidence of admissions to the intensive care unit (ICU)
None of the trials reported this outcome.
6. Buccal midazolam versus intravenous diazepam
One trial (Talukdar 2009), recruiting 120 participants, compared
buccal midazolam to intravenous diazepam.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used.
There was no statistically significant difference in seizure cessa-
tion rates between the groups treated with buccal midazolam or
intravenous diazepam: RR 0.91, 95% CI 0.80 to 1.03, P = 0.15,
high-quality evidence, Analysis 6.1. Both treatments were effec-
tive, with 85% seizure cessation rate for buccal midazolam and
93% for intravenous diazepam.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
The time to control of the seizure from drug administration (time
for drug effect) was significantly shorter for intravenous diazepam
compared to buccal midazolam (mean difference 0.56 minutes,
95% CI 0.29 to 0.83, P < 0.001, moderate-quality evidence,
Analysis 6.2). However the mean time for initiation of treatment
was significantly shorter in the buccalmidazolam group (mean dif-
ference -1.09 minutes, 95% CI -1.31 to -0.87, P < 0.001, Analysis
6.2), making themean total time to controlling the seizures signif-
icantly shorter in the buccal midazolam group compared to the in-
travenous diazepam group (mean difference -0.59 minutes, 95%
CI -0.96 to -0.22, P = 0.002, Analysis 6.2). The faster drug action
of intravenous diazepam is therefore compromised by the need to
gain intravenous access.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
There were no significant adverse events in either group (high-
quality evidence).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
This outcome was not reported in the trial.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
This outcome was not reported in the trial.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
7. Intranasal midazolam versus intravenous diazepam
Three trials, recruiting 174 participants, compared intranasal mi-
dazolam to intravenous diazepam (Javadzadeh 2012; Lahat 2000;
Mahmoudian 2004).
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Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
Two of the trials reported the number of children with their
presenting seizure(s) stopped by the trial drug (Lahat 2000;
Mahmoudian 2004).
Most of the children in the two trials experienced seizure cessation,
with no statistically significant difference between treatments; RR
0.98, 95% CI 0.91 to 1.06, P = 0.67, 122 children, moderate-
quality evidence, Analysis 7.1. There was no heterogeneity present
in the analysis (I2 = 0%).
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
Lahat 2000 reported that the mean time for initiation of treat-
ment was significantly shorter in the intranasal midazolam group
compared to the intravenous diazepam group (mean difference -
2.00 minutes, 95% CI -3.03 to -0.97, P < 0.001, 52 children,
Analysis 7.2). Mahmoudian 2004 also stated that the time from
seizure onset to treatment was faster in the midazolam group due
to cannula insertion in the diazepam group (numerical data not
reported).
There was no statistically significant difference between groups in
two trials (Lahat 2000;Mahmoudian 2004) in the time to control
of the seizure from drug administration (time for drug effect):
mean difference 0.62 minutes, 95% CI -0.14 to 1.38, P = 0.11,
122 children, moderate-quality evidence, Analysis 7.2.
Overall, the mean total time to controlling the seizures was signifi-
cantly shorter in the intravenous diazepam group compared to the
intranasal midazolam group in two trials (Javadzadeh 2012; Lahat
2000): mean difference 0.80, 95% CI 0.24 to 1.35, P = 0.005,
112 children, Analysis 7.2. There is considerable heterogeneity in
this analysis (I2 = 85%), which probably originated from the cal-
culation of the total time to controlling seizures in the Javadzadeh
2012 trial, which seems to adjust for the time taken to insert an
intravenous line.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
Lahat 2000 and Mahmoudian 2004 stated that no adverse events,
including respiratory depression, occurred in either group (high-
quality evidence).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
None of the trials reported this outcome.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
None of the trials reported this outcome.
3. Incidence of admissions to the intensive care unit (ICU)
Mahmoudian 2004 stated that no children required admission to
the ICU (high-quality evidence).
8. Intranasal midazolam and rectal diazepam
One trial (Fi gin 2002), recruiting 45 participants, compared in-
tranasal midazolam and rectal diazepam.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
Intranasal midazolam was significantly more effective than rectal
diazepam in stopping seizures within 10 minutes; 20/23 children
with stopped seizures in the intranasal midazolam group, com-
pared to 13/22 in the rectal diazepam group: RR 1.47, 95% CI
1.00 to 2.16, P = 0.05, low-quality evidence, Analysis 8.1.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion.
This outcome was not reported in the trial.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
There was no significant difference between the two groups for of
cardiorespiratory or adverse effects (low-quality evidence).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
The requirement for a second drug to treat the seizures was higher
in the rectal diazepam group (9/22 children compared to 3/23
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children in the intranasal midazolam group), but this was not
statistically significant; RR 0.32, 95% CI 0.10 to 1.03, P = 0.06,
low-quality evidence, Analysis 8.2.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
Data were only collected for one hour after seizure onset, so there
is no information about seizure recurrence over 24 hours in Fi gin
2002.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
9. Intramuscular midazolam versus intravenous
diazepam
Two trials, recruiting 138 participants, compared intramuscular
midazolam to intravenous diazepam (Chamberlain 1997; Shah
2005). Shah 2005 included some non-randomised participants
who received intravenous diazepam as they already had intra-
venous access; only randomised children are reported in this re-
view. Chamberlain 1997 reported that one child was enrolled in
the study twice, so is represented in both groups. It was not pos-
sible to identify this child in the reported results so we note that
results presented in this section must be interpreted with caution,
due to the representation of this child in both treatment groups.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
Both trials reported the number of children with their present-
ing seizure(s) stopped by the trial drug.There was no statistically
significant difference between the treatments; RR 0.97, 95% CI
0.87 to 1.09, P = 0.66, low-quality evidence, Analysis 9.1. There
was no heterogeneity present in the analysis (I2 = 0%).
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
Chamberlain 1997 reported that the time after arrival to initiat-
ing treatment was shorter in the intramuscular midazolam group
compared to the intravenous diazepam group (mean difference -
4.50 minutes, 95% CI -6.68 to -2.32, P < 0.001, 24 children,
Analysis 9.2) and that this offsets the time to drug effect of the
two treatments (mean difference 1.10 minutes, 95% CI -0.91 to
3.11, P = 0.28, Analysis 9.2), resulting in an overall shorter time
to cessation of seizures in the intramuscular midazolam group.
This is demonstrated in both trials, with the mean total cessation
time converted from seconds to minutes to allow meta-analysis;
mean difference -2.68 minutes, 95% CI -3.94 to -1.42, P < 0.001,
105 children, very low-quality evidence, Analysis 9.2
Chamberlain 1997 also reported that delayed seizure control (be-
tween five and 10 minutes) occurred in four midazolam partici-
pants and one diazepam participant, but this did not reach statis-
tical significance.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously- administered
anticonvulsant
Chamberlain 1997 reported that there were no significant com-
plications. Shah 2005 reported that there were no occurrences of
hypotension or respiratory depression, but identified an important
adverse effect in that seven (10.8%) of the children treated with
intravenous diazepam developed thrombophlebitis, while none in
the intramuscular midazolam group had complications.
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
Both trials reported the number of children requiring additional
drugs to stop their presenting seizure(s).There was no statistically
significant difference between the treatments; RR 1.34, 95% CI
0.35 to 5.13, P = 0.67, 105 children, very low-quality evidence,
Analysis 9.3. There was no heterogeneity in the analysis (I2 = 0%).
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
Chamberlain 1997 reported that after initial seizure cessation four
participants in each group had recurrent seizures requiring further
medication, with one child from each group having a recurrence
within the first 15 minutes. There was no statistically significant
difference between groups at 15 minutes (RR 0.85, 95% CI 0.06
to 12.01, P = 0.90) or at one hour (RR 0.85, 95%CI 0.27 to 2.62,
P = 0.77, very low-quality evidence, Analysis 9.4). Shah 2005 did
not report this outcome.
3. Incidence of admissions to the intensive care unit (ICU)
Shah2005 reported that therewere no ICUadmissions (moderate-
quality evidence). Chamberlain 1997 did not report this outcome.
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10. Intramuscular midazolam versus rectal diazepam
One trial (Momen 2015), recruiting 100 participants, compared
intramuscular midazolam to rectal diazepam.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
Presenting convulsions were stopped for most participants (48/
50 in the intramuscular midazolam group and 47/50 in the rectal
diazepam group) with no significant difference between the treat-
ments: RR 1.02, 95%CI 0.93 to 1.12, P = 0.65, moderate-quality
evidence, Analysis 10.1.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
Time from administration of drug to seizure cessation was ex-
pressed in terms of medians inMomen 2015, so we cannot present
data as a forest plot for this review and we report the results nar-
ratively.
There was a statistically significant difference in time from admin-
istration to seizure cessation in favour of midazolam: median 66
seconds; diazepam: median 130 seconds, P < 0.001 (moderate-
quality evidence). We note that the speed of administration was
similar for both medications, so this seems to reflect a medication
difference.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
No participants developed respiratory depression, except for one
child who received an accidental double-dose of midazolam (mod-
erate-quality evidence).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
This outcome was not reported in the trial.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
Among those who achieved seizure cessation (see Analysis 10.1),
there was no recurrence within 60 minutes (moderate-quality ev-
idence). No data are available for recurrence up to 24 hours.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
11. Intravenous midazolam versus intravenous
diazepam
One trial (Gathwala 2012), recruiting 80 participants, compared
intravenous midazolam to intravenous diazepam.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
The presenting seizure was stopped in most children, with no
statistically significant difference between treatment groups: RR
1.08, 95% CI 0.97 to 1.21, P = 0.17, moderate-quality evidence,
Analysis 11.1.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
There was no statistically significant difference between treatments
in the time to cessation of seizures; mean difference 7.68 seconds,
95% CI -6.73 to 22.09, P = 0.30, moderate-quality evidence,
Analysis 11.2.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
One child in the intravenous diazepam group and no children in
the intravenous midazolam group experienced respiratory depres-
sion; this difference was not statistically significant: RR 0.33, 95%
CI 0.01 to 7.95, P = 0.50, moderate-quality evidence, Analysis
11.3. Gathwala 2012 also reported that there was a significant in-
crease in somnolence in the diazepam compared to themidazolam
groups, but that other adverse effects were evenly distributed.
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
There was no statistically significant difference between treatments
in the number of children requiring an additional dose of the trial
drug to stop the seizure (one child in the midazolam group and
four children in the diazepam group); RR 0.25, 95% CI 0.03 to
2.14, P = 0.21, moderate-quality evidence, Analysis 11.4.
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2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
There was no statistically significant difference between treatment
groups in the number of children with seizure recurrence within
24 hours (two children in the midazolam group and four children
in the diazepam group); RR 0.50, 95% CI 0.10 to 2.58, P = 0.41,
moderate-quality evidence, Analysis 11.5.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
12. Intravenous midazolam versus intravenous
lorazepam
One trial (Gathwala 2012), recruiting 80 participants, compared
Intravenous midazolam to intravenous lorazepam.
Primary outcomes
1. Presenting convulsion/episode of convulsive status
epilepticus stopped with the drug(s) used
The presenting seizure was stopped in most children in the
Gathwala 2012 trial; there was no statistically significant differ-
ence between treatment groups; RR 0.98, 95% CI 0.91 to 1.04,
P = 0.48, moderate-quality evidence, Analysis 12.1.
2. Time taken from administration of any drug in the
hospital to stopping of the convulsion
There was no significant difference between treatment groups in
the time to cessation of seizures; mean difference 1.50 seconds,
95% CI -9.37 to 12.37, P = 0.79, moderate-quality evidence,
Analysis 12.2.
3. The incidence of specific adverse effects: respiratory
depression/arrest; cardiac arrhythmia; hypotension and
extravasation of any intravenously-administered
anticonvulsant
There were no occurrences of respiratory depression in either
group in the Gathwala 2012 trial. Gathwala 2012 also reported
that other adverse effects were evenly distributed between the
groups (high-quality evidence).
Secondary outcomes
1. The need to use additional anti-epileptic drugs to stop the
presenting convulsion
There was no statistically significant difference between treatment
groups in the number of children requiring an additional dose of
the trial drug to stop the seizure (one child in themidazolam group
and no children in the lorazepam group); RR 3.00, 95% CI 0.13
to 71.51, P = 0.50, moderate-quality evidence, Analysis 12.3.
2. Recurrence of convulsions within 24 hours from stopping
of the presenting convulsion
There was no statistically significant difference between treatment
groups in the number of children with seizure recurrence within
24 hours (two children in each group); RR 1.00, 95% CI 0.15 to
6.76, P = 1.00, moderate-quality evidence, Analysis 12.4.
3. Incidence of admissions to the intensive care unit (ICU)
This outcome was not reported in the trial.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intranasal lorazepam compared with intramuscular paraldehyde for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intranasal lorazepam
Comparison: Intramuscular paraldehyde
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intramuscular paralde-
hyde
Intranasal lorazepam
Seizure cessation:
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RR 1.22
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Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
138 per 1000 100 per 1000
(43 to 235)
RR 0.73
(0.31 to 1.71)
160
(1 study)
⊕⊕©©
low1,3
-
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to applicability: a high proport ion of the children recruited had either cerebral malaria or meningit is.
These comorbidit ies may have impacted upon the results.
2Downgraded once due to imprecision: no numerical data reported.
3Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to low event numbers in one or
both treatment groups).
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Intravenous lorazepam compared with intravenous diazepam/ intravenous phenytoin combination for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intravenous lorazepam
Comparison: Intravenous diazepam/ intravenous phenytoin combinat ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous diazepam/
intravenous phenytoin
combination
Intravenous lorazepam
Seizure cessation:
within 10 minutes
Follow-up: up to 24
hours
Seizures were stopped
for all individuals in the
Intravenous diazepam/
intravenous phenytoin
combinat ion group
Seizures were stopped
for all individuals in the
Intravenous lorazepam
group
RR 1.00
(0.98 to 1.02)
178
(1 trial)
⊕⊕⊕©
moderate1
-
Time from drug admin-
istration to stopping of
seizures
Follow-up: up to 24
hours
There was no signif icant dif f erence in the median
t ime to seizure cessat ion (20 seconds in each
group)
NA 178
(1 trial)
⊕⊕⊕©
moderate2
-
Incidence of respira-
tory depression
Follow-up: up to 24
hours
57 per 1000 44 per 1000
(13 to 160)
RR 0.78
(0.22 to 2.82)
178
(1 trial)
⊕⊕⊕©
moderate3
-
Additional drugs re-
quired to stop the
seizure
Follow-up: up to 24
159 per 1000 67 per 1000
(27 to 165)
RR 0.42
(0.17 to 1.04)
178
(1 trial)
⊕⊕⊕©
moderate3
-
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Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
There were no seizure recurrences in either
group.
NA 178
(1 trial)
⊕⊕⊕©
moderate4
-
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due toapplicability: Both treatment arms showed a 100% seizure cessat ion rate, which is higher than
expected. Unclear whether this high success rate was due to a part icular element of the trial design.
2Downgraded once due to imprecision: lim ited numerical data reported.
3Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to low event numbers in one or
both treatment groups).
4Downgraded once due to applicability: the control intervent ion included a long-act ing ant i-convulsant (phenytoin) which may
have inf luenced the seizure recurrence rate in the control group.
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Intravenous lorazepam compared with intranasal lorazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intravenous lorazepam
Comparison: Intranasal lorazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intranasal lorazepam Intravenous lorazepam
Seizure cessation:
within 10 minutes
Follow-up: up to 24
hours
696 per 1000 744 per 1000
(536 to 1000)
RR 1.07
(0.77 to 1.49)
58
(1 trial)
⊕⊕⊕©
moderate 1
There was also no sig-
nif icant dif f erence be-
tween treatments for
seizure cessat ion at 1
hour: RR 0.70 (95% CI
0.43 to 1.17)
Time from drug admin-
istration to stopping of
seizures
Follow-up: up to 24
hours
Median t ime to achieve seizure control f rom drug
administrat ion was 4 minutes in both groups
NA 58
(1 trial)
⊕⊕⊕©
moderate2
Time taken
to achieve intravenous
access ranged f rom 1
to 25 minutes with a
median of 4 minutes
across all part icipants
in the trial. If this had
been included in the
response t ime for the
intravenous lorazepam,
the results would have
been skewed signif i-
cant ly in favour of in-
tranasal lorazepam
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Incidence of respira-
tory depression
Follow-up: up to 24
hours
One child required res-
piratory support
Two children required
respiratory support
NA 141
(1 trial, see comment)
⊕⊕⊕©
moderate3
Incidence of respira-
tory depression was not
reported for the sub-
group of part icipants
with generalised tonic-
clonic seizures in the
trial, therefore these
results refer to all
part icipants (including
83 part icipants with-
out generalised tonic-
clonic seizures)
Additional drugs re-
quired to stop the
seizure
Follow-up: NA
Outcome not reported NA -
Seizure recurrence
within 24 hours
Follow-up: NA
Outcome not reported NA -
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Downgraded once due to imprecision: imbalance in the number of part icipants randomised to each intervent ion with
generalised tonic-clonic seizures and overall direct ion of ef fect seems to change when measured at 10 minutes or at 1 hour
2Downgraded once due to imprecision: lim ited numerical data reported.
3Downgraded once due to imprecision: Low event numbers and outcome data not available for the subgroup part icipants with
generalised tonic-clonic seizures in the trial
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Buccal midazolam compared with rectal diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Buccal m idazolam
Comparison: Rectal diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Rectal diazepam Buccal midazolam
Seizure cessation:
within 5 minutes to 1
hour
Follow-up: up to 24
hours
584 per 1000 730 per 1000
(660 to 806)
RR 1.25
(1.13 to 1.38)
648
(4 trials)
690 seizure episodes
⊕©©©
very low1,2,3
The measurement t ime
of seizure cessat ion
was examined in a sub-
group analysis
5 minutes: RR1.22 (95%
CI 1.07 to 1.40, P = 0.
004);
10 minutes: RR 1.07
(95% CI 0.95 to 1.21, P
= 0.26);
1 hour; RR 2.05 (95%CI
1.45 to 2.91, P < 0.001)
.
There was a signif icant
dif f erence between the
subgroups (P = 0.002)
Time from drug admin-
istration to of seizures
Follow-up: up to 24
hours
One trial found no dif ference between groups
in the t ime f rom drug administrat ion to seizure
cessat ion
One trial reported that both the median treatment
init iat ion t ime and drug ef fect t ime were signif -
icant ly shorter in the buccal m idazolam group
NA 141
(2 trials)
⊕⊕©©
low1,4
No numerical data pre-
sented for either trial
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than the rectal diazepam group
Incidence of respira-
tory depression
Follow-up: up to 24
hours
76 per 1000 67 per 1000
(46 to 94)
RR 0.88
(0.61 to 1.25)
648
(4 trials)
690 seizure episodes
⊕⊕©©
low1,3
-
Additional drugs re-
quired to stop the
seizure: intravenous lo-
razepam required
Follow-up: up to 24
hours
573 per 1000 332 per 1000
(241 to 452)
RR 0.58
(0.42 to 0.79)
177
(1 trial)
219 seizure episodes
⊕⊕©©
low3,5
A second trial reported
that there was no dif fer-
ence between groups in
the need for a second
drug
Seizure recurrence
within 24 hours
Follow-up: NA
Outcome not reported NA -
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: one included study was quasi-randomised and one study did not conceal allocat ion.
Both of these studies were at risk of select ion bias.
2Downgraded once due to inconsistency: a high proport ion of heterogeneity was present in analysis, probably due to
dif ferences in the measurement t imes of the outcome and potent ially also the doses of the drugs across the studies and
comorbidit ies of part icipants recruited.
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3Downgraded once due to imprecision: Results are not available at the part icipant level so results reported for McIntyre 2005
are at the episode level. This is a lim itat ion, as meta-analysis assumes independence between measurements, and more than
one treated seizure per part icipant would not be stat ist ically independent. A result of ignoring this unit-of -analysis issue could
be overopt im ist ic conf idence intervals.
4Downgraded once due to imprecision: no numerical data reported.
5Downgraded once due to risk of bias: the included study was quasi-randomised, did not conceal allocat ion and was at risk
of select ion bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Buccal midazolam compared with intravenous diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Buccal m idazolam
Comparison: Intravenous diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous diazepam Buccal midazolam
Seizure cessation
Follow-up: up to 24
hours
933 per 1000 849 per 1000
(747 to 961)
RR 0.91 (0.80 to 1.03) 120
(1 trial)
⊕⊕⊕⊕
high
-
Time from drug admin-
istration to termination
of seizures
Follow-up: up to 24
hours
The mean time to ces-
sat ion of seizures was
1.13 minutes in the
intravenous diazepam
group
The mean time to ces-
sat ion of seizures was
0.56 minutes higher in
the buccal diazepam
group (0.29 to 0.83 min-
utes higher)
NA 120
(1 trial)
⊕⊕⊕©
moderate1
The mean time for init i-
at ion of treatment was
signif icant ly shorter in
the buccal m idazolam
group (MD -1.09 min-
utes, 95% CI -1.31
to -0.87) and there-
fore the mean to-
tal t ime to control-
ling the seizures was
signif icant ly shorter in
the buccal m idazolam
group compared to the
intravenous diazepam
group (MD -0.59, 95%CI
-0.96 to -0.22)
4
0
D
ru
g
m
a
n
a
g
e
m
e
n
t
fo
r
a
c
u
te
to
n
ic
-c
lo
n
ic
c
o
n
v
u
lsio
n
s
in
c
lu
d
in
g
c
o
n
v
u
lsiv
e
sta
tu
s
e
p
ile
p
tic
u
s
in
c
h
ild
re
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Incidence of respira-
tory depression
Follow-up: up to 24
hours
There were no adverse events in either group NA 120
(1 trial)
⊕⊕⊕⊕
high
-
Additional drugs re-
quired to stop the
seizure
Follow-up: NA
Outcome not reported NA -
Seizure recurrence
within 24 hours
Follow-up: NA
Outcome not reported NA -
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; MD: Mean dif ference; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to applicability: the route of intervent ion of the drug has been shown to inf luence the outcome.
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Intranasal midazolam compared with intravenous diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intranasal m idazolam
Comparison: Intravenous diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous diazepam Intranasal midazolam
Seizure cessation
Follow-up: up to 24
hours
967 per 1000 948 per 1000
(880 to 1000)
RR 0.98
(0.91 to 1.06)
122
(2 trials)
⊕⊕⊕©
moderate1
-
Time from drug admin-
istration to stopping of
seizures
Follow-up: up to 24
hours
The mean time to
cessat ion of seizures
ranged f rom 2.5 to
2.94 minutes in the
intravenous diazepam
group
The mean time to ces-
sat ion of seizures was
0.62 minutes higher in
the intranasal m idazo-
lam group (0.14 lower
to 1.38 minutes higher)
NA 122
(2 trials)
⊕⊕⊕©
moderate2
One trial reports that
the t ime for init iat ion
of treatment was sig-
nif icant ly shorter in the
intranasal m idazolam
group (MD -2.00 min-
utes, 95%CI -3.03 to -0.
97). The other trial also
reports that t ime for ini-
t iat ion of treatment was
signif icant ly shorter in
the intranasal m idazo-
lam group but does not
account for this in anal-
ysis
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Incidence of respira-
tory depression
Follow-up: up to 24
hours
No adverse events including respiratory depres-
sion occurred in either group
NA 122
(2 trials)
⊕⊕⊕⊕
high
-
Additional drugs re-
quired to stop the
seizure
Follow-up: NA
Outcome not reported NA -
Seizure recurrence
within 24 hours
Follow-up: NA
Outcome not reported NA -
Incidence of admis-
sions to the ICU
Follow-up: up to 24
hours
There were no admissions to the ICU in either
group
NA 52
(1 trial)
⊕⊕⊕⊕
high
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; MD: Mean dif ference; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: one of the studies included in this comparison did not report this outcome. As this is
an expected outcome, this may be select ive report ing. Addit ionally, in one trial both treatment arms showed a 100%seizure
cessat ion rate, which is higher than expected. Unclear whether this high success rate was due to a part icular element of
the trial design.
2Downgraded once due to applicability: the route of intervent ion of the drug has been shown to inf luence the outcome.
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Intranasal midazolam compared with rectal diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intranasal m idazolam
Comparison: Rectal diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Rectal diazepam Intranasal midazolam
Seizure cessation:
within 10 minutes
Follow-up: up to 24
hours
591 per 1000 869 per 1000
(591 to 1000)
RR 1.47
(1.00 to 2.16)
45
(1 trial)
⊕⊕©©
low1,2
-
Time from drug admin-
istration to termination
of seizures
Follow-up: NA
Outcome not reported NA -
Incidence of respira-
tory depression
Follow-up:
There was no signif icant dif f erence between the
two groups for of cardiorespiratory or adverse
ef fects
NA 45
(1 trial)
⊕⊕©©
low1,3
No numerical data re-
ported
Additional drugs re-
quired to stop the
seizure
Follow-up: up to 24
hours
409 per 1000 131 per 1000
(41 to 421)
RR 0.32
(0.10 to 1.03)
45
(1 trial)
⊕⊕©©
low1,4
-
Seizure recurrence
within 24 hours
Follow-up: NA
Outcome not reported NA -
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Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: one included study was quasi-randomised, which may have led to select ion bias.
Addit ionally, the descript ion of the seizure type and aet iology of the included children was unclear, so it is unclear if the
populat ion of this study is generalisable.
2Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to high event rates in both
treatment groups).
3Downgraded once due to imprecision: no numerical data reported.
4Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to low event rates in both
treatment groups).
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Intramuscular midazolam compared with intravenous diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intramsucular m idazolam
Comparison: Intravenous diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous diazepam Intramsucular midazo-
lam
Seizure cessation
Follow-up: up to 24
hours
929 per 1000 901 per 1000
(808 to 1000)
RR 0.97
(0.87 to 1.09)
105
(2 trials)
⊕⊕©©
low1,2
-
Time from drug admin-
istration to stopping of
seizures: total t ime to
seizure cessat ion
Follow-up: up to 24
hours
The mean total t ime to cessat ion of seizures was
2.68 minutes lower (3.94 to 1.42 minutes lower)
in the intramuscular m idazolam group compared
to the intravenous diazepam group
NA 105
(2 trials)
⊕©©©
very low1,2,3
One trial also showed
that the init iat ion of
treatment was signif -
icant ly shorter in the
intramuscular m idazo-
lam group (MD -4.50
minutes (-6.68 to -2.32)
) but there was no sig-
nif icant dif f erence be-
tween treatments for
the t ime to drug ef fect
(MD 1.10 minutes (95%
CI -0.91 to 3.11)
Incidence of respira-
tory depression
Follow-up: up to 24
hours
There were no adverse events or complicat ions
in either trial
NA 105
(2 trials)
⊕⊕©©
low1,2
-
4
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Additional drugs re-
quired to terminate the
seizure
Follow-up: up to 24
hours
71 per 1000 96 per 1000
(25 to 366)
RR 1.34
(0.35 to 5.13)
105
(2 trials)
⊕©©©
very low1,2,4
-
Seizure recurrence
within 24 hours: within
one hour
Follow-up: up to 24
hours
364 per 1000 309 per 1000
(98 to 983)
RR 0.85
(0.27 to 2.62)
24
(1 trial)
⊕©©©
very low1,2,4
There was also no sig-
nif icant dif f erence be-
tween treatments at
within 15 minutes (RR:
0.85 (95%CI 0.06,to12.
01)
Incidence of admis-
sions to the ICU
Follow-up: up to 24
hours
There were no admissions to the ICU NA 81
(1 trial)
⊕⊕⊕©
moderate1
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; MD: Mean dif ference; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: in both included trials, methods of randomisat ion were unclear so the trials may be at
risk of select ion bias.
2Downgraded once due to applicability: one child was randomised twice in one trial and included in both groups. It was not
possible to ident if y this child in analysis and results are not adjusted for the correlat ion between measurements f rom the
same child.
3Downgraded once due to applicability: the route of intervent ion of the drug has been shown to inf luence the outcome.
4Downgraded once due to imprecision: wide conf idence intervals around the ef fect size or pooled ef fect size (due to low
event rates in both treatment groups).
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Intramuscular midazolam compared with rectal diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intramuscular m idazolam
Comparison: Rectal diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Rectal diazepam Intramuscular midazo-
lam
Seizure cessation
Follow-up: up to 24
hours
940 per 1000 959 per 1000
(874 to 1000)
RR 1.02 (0.93 to 1.12) 100
(1 trial)
⊕⊕⊕©
moderate1
-
Time from drug admin-
istration to stopping of
seizures
Follow-up: up to 24
hours
There was a signif icant dif f erence in t ime f rom
administrat ion to seizure cessat ion in favour
of m idazolam (median 66 seconds, diazepam,
median 130 seconds, P < 0.001)
NA 100
(1 trial)
⊕⊕⊕©
moderate1
It is noted that the
speed of administra-
t ion was sim ilarly fast
for both medicat ions,
so this seems to ref lect
a medicat ion dif ference
Incidence of respira-
tory depression
Follow-up: up to 24
hours
No patients developed respiratory depression
except for one pat ient who received an accidental
double dose of intramuscular m idazolam
NA 100
(1 trial)
⊕⊕⊕©
moderate1
-
Additional drugs re-
quired to stop the
seizure
Follow-up: NA
Outcome not reported NA -
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Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
Among those with seizures term inated, there
were no recurrences at 24 hours
NA 100
(1 trial)
⊕⊕⊕©
moderate1
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: the included study did not conceal allocat ion so is at risk of select ion bias.
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Intravenous midazolam compared with intravenous diazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intravenous midazolam
Comparison: Intravenous diazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous diazepam Intravenous midazo-
lam
Seizure cessation
Follow-up: up to 24
hours
900 per 1000 972 per 1000
(873 to 1000)
RR 1.08
(0.97 to 1.21)
80
(1 trial)
⊕⊕⊕©
moderate1
-
Time from drug admin-
istration to stopping of
seizures
Follow-up: up to 24
hours
The mean time to ces-
sat ion of seizures was
84.94 seconds in the
intravenous diazepam
group
The mean time to ces-
sat ion of seizures was
7.68 seconds higher in
the intravenous mida-
zolam group (6.73 sec-
onds lower to 22.09
seconds higher)
NA 80
(1 trial)
⊕⊕⊕©
moderate2
-
Incidence of respira-
tory depression
Follow-up: up to 24
hours
25 per 1000 8 per 1000
(0 to 199)
RR 0.33 (0.01 to 7.95) 80
(1 trial)
⊕⊕⊕©
moderate3
-
Additional
drugs required to stop
the seizure: addit ional
dose of the trial drug re-
quired
100 per 1000 25 per 1000
(3 to 214)
RR 0.25
(0.03 to 2.14)
80
(1 trial)
⊕⊕⊕©
moderate3
-
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Follow-up: up to 24
hours
Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
100 per 1000 50 per 1000
(10 to 258)
RR 0.50 (0.10 to 2.58) 80
(1 trial)
⊕⊕⊕©
moderate3
-
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: the def init ion of the ’seizure cessat ion’ outcome is not an appropriate criterion for
judging seizure cessat ion. This def init ion is likely to have impacted upon results.
2Downgraded once due to imprecision: wide conf idence intervals around the ef fect size.
3Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to low event rates in both
treatment groups).
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Intravenous midazolam compared with intravenous lorazepam for children with acute tonic-clonic seizures
Patient or population: Children with acute tonic-clonic seizures
Settings: Hospital inpat ients
Intervention: Intravenous midazolam
Comparison: Intravenous lorazepam
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intravenous lorazepam Intravenous midazo-
lam
Seizure cessation
Follow-up: up to 24
hours
Seizures were term i-
nated for all children
in the Intravenous lo-
razepam group
Seizures were term i-
nated for 39 out of
40 children in the in-
travenous midazolam
group
RR 0.98 (0.91 to 1.04) 80
(1 trial)
⊕⊕⊕©
moderate1
-
Time from drug admin-
istration to termination
of seizures
Follow-up: up to 24
hours
The mean time to ces-
sat ion of seizures was
91.12 seconds in the
intravenous lorazepam
group
The mean time to ces-
sat ion of seizures was
1.50 seconds higher in
the intravenous mida-
zolam group (9.37 sec-
onds lower to 12.37
seconds higher)
NA 80
(1 trial)
⊕⊕⊕©
moderate2
-
Incidence of respira-
tory depression
Follow-up: up to 24
hours
There were no occurrences of respiratory depres-
sion in either group
NA 80
(1 trial)
⊕⊕⊕⊕
high
-
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Additional drugs re-
quired to terminate
the seizure: addit ional
dose of the trial drug re-
quired
Follow-up: up to 24
hours
No children in the
intravenous lorazepam
group required an addi-
t ional dose of the trial
drug
One child in the in-
travenous midazolam
group required an addi-
t ional dose of the trial
drug
RR 3.00 (0.13 to 71.51) 80
(1 trial)
⊕⊕⊕©
moderate3
-
Seizure recurrence
within 24 hours
Follow-up: up to 24
hours
50 per 1000 50 per 1000
(8 to 338)
RR 1.00 (0.15 to 6.76) 80
(1 trial)
⊕⊕⊕©
moderate3
-
Incidence of admis-
sions to the ICU
Follow-up: NA
Outcome not reported NA -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; ICU: Intensive Care Unit ; NA: Not applicable; RR: Risk Ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded once due to risk of bias: the def init ion of the ’seizure cessat ion’ outcome is not an appropriate criterion for
judging seizure cessat ion. This def init ion is likely to have impacted upon results.
2Downgraded once due to imprecision: wide conf idence intervals around the ef fect size.
3Downgraded once due to imprecision: wide conf idence intervals around the ef fect size (due to low event rates in both
treatment groups).
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D I S C U S S I O N
Summary of main results
The 14 newly-identified studies in this updated review include
a range of drug treatment options (midazolam, diazepam, lo-
razepam, paraldehyde and phenytoin), treatment doses (for the
same drug) and a range of routes of administration (rectal, buc-
cal, nasal, intramuscular and intravenous). A number of the new
studies have evaluated and emphasised the use of non-intravenous
routes. These have included intranasal, intramuscular and buccal
routes. The role of the intramuscular route in children is uncer-
tain, particularly in view of its relatively invasive nature as well as
potentially serious complications, including trauma to the sciatic
nerve.
The 18 studies included in this review vary by design, setting and
populations, in their ages and also in their clinical situation. We
have conducted many comparisons of drugs and of routes of ad-
ministration of drugs in this review, with the quality of the ev-
idence for each comparison varying from high to very low, de-
pending on the homogeneity and quality of design of the studies
contributing to the comparison.
This update has shown that for intravenous administration, lo-
razepam and diazepam seem to be associated with similar rates of
seizure cessation (Appleton 1995; Chamberlain 2014; Gathwala
2012), but risks of bias in the included studies and heterogeneity
of design may have confounded the results.
Two studies in this update have shown that buccal midazolammay
be associated with a higher rate of seizure cessation than rectal
diazepam (Ashrafi 2010; Mpimbaza 2008). However, we are very
uncertain about the estimate of this effect. In part, this reflects
the different range of doses of buccal midazolam used in these
studies and the different characteristics of their participants. A
single study also provides moderate- to high-quality evidence that
buccal midazolam may be associated with a higher rate of seizure
cessation than intravenous diazepam (Talukdar 2009). However,
as for all studies included within this review, with different routes
of administration, time to cessation of seizures was influenced by
the way it was delivered.
There are currently insufficient data to determine whether there
are any significant or clinically important differences in efficacy
or safety between the buccal and intranasal routes of administra-
tion of midazolam; this issue will only be resolved by at least one
robust RCT that compares buccal to intranasal midazolam. The
intranasal route of administration was used in five studies and was
compared with rectal or intravenous routes (Ahmad 2006; Arya
2011; Fi gin 2002; Javadzadeh 2012; Mahmoudian 2004). Gen-
erally, the intranasal/buccal/intramuscular routes appear to show
similar rates of the most common (and most clinically impor-
tant) primary outcome, seizure cessation, compared to intravenous
routes of administration. However, the rapid action of the intra-
venously-administered drug is compromised by the time taken to
achieve intravenous access. This was particularly demonstrated in
three studies (Arya 2011; Shah 2005; Talukdar 2009). This is an
important issue, particularly in infants but also in older children
who are in shock with circulatory collapse, and where intravenous
access is likely to be more difficult and therefore delay effective
anticonvulsive treatment.
Adverse side effectswere observed very infrequently in the included
studies. Respiratory depression was the most common and most
clinically relevant side effect. Where reported in the study, the
frequency ranged from none (Ashrafi 2010; Chamberlain 1997;
Fi gin 2002; Mahmoudian 2004; Shah 2005; Talukdar 2009), to
1% to 2% (Arya 2011), almost 6% (Sreenath 2010) and up to
almost 18% (Chamberlain 2014). The latter study defined respi-
ratory depression as ‘assisted ventilation’; the incidence of respi-
ratory depression is considerably higher than in the other stud-
ies that reported this outcome. None of the studies individually
demonstrated any difference in the rates of respiratory depression
between the different anticonvulsants or their different routes of
administration; but when pooled, three studies provided moder-
ate-quality evidence that lorazepam was significantly associated
with fewer occurrences of respiratory depression than diazepam
(RR 0.72, 95% CI 0.55 to 0.93).
Overall completeness and applicability of
evidence
The evidence presented in previous versions of the review has sup-
ported previously-published open, anecdotal data. Buccal midazo-
lam has become established as the first-line non-intravenous drug,
and intravenous lorazepam has become established as the first-line
intravenous drug in treating an acute tonic-clonic convulsion (and
established convulsive status epilepticus) in children. The evidence
has contributed to the evidence base for the Status Epilepticus
Working Group to revise the convulsive status epilepticus guide-
line which was first published in 2000 (Working Party 2000) and
has been incorporated into the partially revised and updated Na-
tional Institute for Health and Care Excellence (NICE) Clinical
Guideline in Epilepsy (NICE 2012) and the Advanced Paediatric
Life Support (APLS) guidelines (APLS 2016).
Most studies were undertaken in unselected populations of chil-
dren presenting to the Emergency Department (ED) of a single
centre, or a group of centres (between three and 11) based either
in a general or a children’s hospital. Consequently, these data are
likely to be generalisable and applicable to other children with
acute tonic-clonic convulsions in this clinical situation. However,
there were two studies undertaken in a very specific population,
of African children, in whom cerebral malaria was the cause of
the convulsion in 49% to 67% (Ahmad 2006; Mpimbaza 2008
respectively). The treatment arms in Ahmad 2006 were somewhat
unusual, comprising intranasal lorazepam and intramuscular par-
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aldehyde; no other study used these treatments. The authors jus-
tified the use of paraldehyde on the basis of it’s being the “first or
second-line anticonvulsant agent in much of sub-Saharan Africa
because of its favourable safety and efficacy profile”. Paraldehyde
has been used as an anticonvulsant for over 50 years. It is currently
used when other anticonvulsants, including benzodiazepines or
phenytoin and phenobarbital, have failed to stop an acute tonic-
clonic convulsion and is often effective (Rowland 2009). The rec-
tal route is preferred, because of the risk of sterile abscesses and
damage to the sciatic nerve with the intramuscular route. Rectal
paraldehyde is included in the UK’s APLS algorithm (APLS 2016)
for the management of status epilepticus.
Two early studies (Chamberlain 1997; Lahat 2000) used a seizure
duration of 10 rather than five minutes as the time to institute
emergency treatment; all other studies used five or “at least 5”
minutes, which is standard international practice.
The age range of the children in the 18 studies varied between
birth and under 18 years.Most assessed children aged two months
to 12 or 15 years, although two assessed amuch narrower age range
from twomonths to approximately five years (Ahmad 2006; Lahat
2000).Most epidemiological studies have demonstrated that more
than 80% of children who present with an acute tonic-clonic con-
vulsion, including convulsive status epilepticus, are under 10 years
of age, and of these most will be under five years of age. In addi-
tion, most causes of convulsive status epilepticus in children under
five will be febrile status or due to an acute symptomatic cause.
Consequently, this might introduce some bias in those studies that
assessed only young children.
Quality of the evidence
The extent of the evidence provided by this updated review, both
in terms of the 14new studies (making a total of 18 and comprising
2199participants) and their scientific robustness, has strengthened
its quality and its conclusions. We have consequently achieved
some of the objectives of the review.
Much of the evidence provided in this review is of moderate to
high quality. However, the quality of the evidence provided for
some important outcomes is low to very low, particularly for com-
parisons of non-intravenous routes of drug administration. We
downgraded the quality of the evidence due to imprecise results
where limited data were available for analysis or where confidence
intervals of effect sizes were wide, making interpretation of results
difficult. Quality of the evidence was also downgraded due to the
methodological inadequacies of some studies which may have in-
troduced bias into the results, to study settings which were not
applicable to wider clinical practice, and to inconsistency in some
pooled analyses.
The dose of lorazepam in all preparations (predominantly intra-
venous, but also rectal and intranasal) was the same in all six stud-
ies where it was a treatment arm (0.1 mg/kg). In contrast, the dose
of midazolam (in predominantly buccal but also intranasal prepa-
ration) ranged from 0.2 to 0.5 mg/kg, and the dose of either rectal
or intravenous diazepam varied from 0.2 to 0.5 mg/kg. The rea-
sons for the wide range of doses are not clear. Previous studies had
not suggested that respiratory depressionwas a significant problem
with doses of buccal midazolam of 0.5 mg/kg (McIntyre 2005),
and the methodology and findings of this large study would have
helped to inform subsequent studies on an effective and safe dose.
One potential bias throughout all the studies is how the original
trial authors defined cessation of the seizure or convulsion fol-
lowing the intervention. Observer variation and inconsistency is
well recognised when deciding when a tonic-clonic convulsion has
stopped. A proposed definition by Appleton (personal opinion) is
that a tonic-clonic convulsion has stopped when there is “no visi-
ble sign of ongoing rhythmic clonic activity”. The included stud-
ies’ definitions of seizure cessation ranged from no definition to
“the practitioner’s clinical judgement” to “generalized convulsions
have stopped”, “cessation of all visible convulsive activity”, “cessa-
tion of all visible motor seizure activity” or “cessation of all motor
activity”. The use of ‘motor activity’ is arguably too vague, as the
brief, asymmetric and asynchronous myoclonus that commonly
follows a tonic-clonic seizure may be misinterpreted as “ongoing
motor activity”; this is likely to impact on the efficacy result and
lead to bias between studies.
Potential biases in the review process
It is unlikely that the methods used in this updated review will
have introduced any significant bias. We successfully addressed
outstanding queries and resolved them in most cases by personal
contact with the leading or corresponding authors of the included
studies.
We identified all relevant new studies, as far as we could ascer-
tain. The methodology of most of the new studies was more ro-
bust than those included in the first review. However, there was
some variation in methodology and the reporting of results be-
tween these studies, as detailed earlier in the review. Two of the 18
studies reported 100% seizure cessation in both treatment arms
(Mahmoudian 2004; Sreenath 2010), and in one treatment arm
(Ashrafi 2010), which is unusual as the median seizure-cessation
rate was approximately 75% in all other studies. In addition, the
dose of intravenous diazepam in the two studies that reported
100% seizure cessation in both was the lowest used throughout
the included studies (0.2 mg/kg).
Agreements and disagreements with other
studies or reviews
This review is in broad general agreement with the recently-pub-
lished Evidence-based guideline on the treatment of convulsive sta-
tus epilepticus in children and adults, published by the Guideline
Committee of the American Epilepsy Society (Glauser 2016).
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Our findings are also consistent with a recent meta-analysis
(McMullan 2010) of midazolam versus diazepam in children and
young adults which included many of the studies in this review.
They also concluded that non-intravenous midazolam was as ef-
fective as intravenous diazepam and that buccal midazolam was
superior to rectal diazepam.
The above studies would appear to have been subjected to a similar
systematic review process.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This updated review provides limited and low- or very-low qual-
ity evidence regarding the use of buccal midazolam as the first-
line treatment for an acute tonic-clonic convulsion and convul-
sive status epilepticus in children where intravenous access is not
available. Limited new data, of moderate to low quality, shows no
clear differences between intravenous lorazepam and intravenous
diazepam as the first-line intravenous drug in the management of
acute tonic-clonic convulsions in children. The review provides
limited and low-quality evidence that the intranasal route, using ei-
ther lorazepam or midazolam, may be an effective alternative non-
intravenous route of administration to stop tonic-clonic seizures.
This is of particular importance in countries with a high incidence
of central nervous system infectious diseases, where children often
present late and in shock, making it difficult to obtain rapid in-
travenous access, and where intravenous cannulae and equipment
are likely to be in limited supply.
Implications for research
This review has identified a large number of new randomised
clinical trials since 2007. Despite these new data, much was of
low quality for important comparisons. Consequently, there is a
clear need for additional paediatric randomised controlled trials
of the treatment of acute tonic-clonic convulsions and convulsive
status epilepticus. Potential areas for research and specifically for
randomised controlled trials include:
• Efficacy of commonly-used first-line treatments such as
lorazepam and midazolam, mode of delivery including data on
optimal drug doses, and timing of interventions. The most
appropriate randomised control trial would use a factorial design
to compare drugs and modes of delivery efficiently.
• Role and efficacy of pre-hospital medications, usually
benzodiazepines, administered by parents, carers or paramedical
staff.
• Efficacy and safety of second-line treatments, including
fosphenytoin, phenobarbital, phenytoin and sodium valproate.
• The role of rectal paraldehyde.
• The potential efficacy and safety of newer anticonvulsants,
including intravenous levetiracetam and lacosamide.
The pre-hospital treatment of acute tonic-clonic convulsions is
not within the remit of this review. However, it seems appropriate
to comment on possible future research initiatives. Traditionally,
rectal diazepam has been the preferred pre-hospital rescue (emer-
gency) medication, but this has now been replaced by buccal mi-
dazolam in routine clinical practice in the UK and the rest of Eu-
rope. This has been on the basis of midazolam’s perceived similar
or slightly superior efficacy to diazepam, and its easier and more
acceptable route of administration by carers, school nurses and
teaching staff. More recently, pre-hospital randomised controlled
trials have examined the role of intramuscular midazolam admin-
istered by paramedics in acute tonic-clonic convulsions, including
status epilepticus. The Rapid Anticonvulsant Medication Prior to
Arrival Trial (RAMPART) was a double-blind randomised, non-
inferiority clinical trial of the efficacy of intramuscular midazo-
lam versus intravenous lorazepam in the pre-hospital treatment of
status epilepticus by paramedics (Silbergleit 2013). A secondary
analysis of the RAMPART study undertaken in children aged un-
der 18 (Welch 2015) showed no statistically significant difference
between the two treatment arms in achieving the study’s primary
outcome, namely seizure cessation prior to arrival in the emer-
gency department. Although intramuscular midazolam might be-
come the preferred pre-hospital, first-line emergency medication
by paramedic staff (as intravenous access may be difficult), this
route is unlikely to be adopted by carers, school nurses and teach-
ers who administer most pre-hospital rescue medications. Never-
theless, it would be interesting to undertake an RCT of intramus-
cular midazolam and buccal midazolam amongst paramedics.
A C K N OW L E D G E M E N T S
Ms Anita Aindow, Pharmacy Department, Alder Hey Children’s
Hospital, Liverpool, UK.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmad 2006
Methods Randomised controlled trial carried out over 12 months in Malawi
Participants 160 children of both sexes and aged 2 months to 12 years presenting to a paediatric
emergency department in a generalised seizure.
Exclusion criteria: features of hepatic or hypertensive encephalopathy or organophos-
phate poisoning, children who had received an anticonvulsant within 1 hour of presen-
tation
Interventions Intranasal lorazepam versus intramuscular paraldehyde
Outcomes Seizure cessation
Incidence of cardiorespiratory depression
Need for further anti-convulsant/s
Notes Study conducted in Africa with a high proportion of children with either cerebral malaria
or meningitis. Consequently, not readily generalisable to western populations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Blocked randomisation was done
in advance by a computer that randomly
generated a table of numbers in batches of
ten“
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Quote: ” treatment allocations were sealed
in unmarked identical envelopes. Investi-
gators were masked to these allocations be-
fore the point of patient treatment
Quote: adequate concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would have
been difficult due to the different routes of
administration of the 2 study drugs. This
is not likely to have affected outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the final analysis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
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Ahmad 2006 (Continued)
Other bias High risk A high proportion of the children recruited
had either cerebral malaria or meningitis.
These comorbidities may have impacted
upon the results
Appleton 1995
Methods Quasi-randomised controlled trial (odd and even days randomisation of the 2 drugs)
over a 12-month study period
Participants 102 children of both sexes and aged < 16 years presenting to a single Accident and
Emergency department in a tonic-clonic convulsion including established convulsive
status epilepticus. Participants treated included those with an established diagnosis of
epilepsy, febrile convulsions and those presenting with a first convulsion.
Exclusion criteria: known pseudo-tonic-clonic convulsions or pseudo-convulsive, ab-
sence or complex partial status
Interventions Lorazepam versus diazepam: rectal and intravenous administration. Diazepam dose: 0.
3 to 0.4 mg/kg and lorazepam dose: 0.05 to 0.1 mg/kg. These doses were used for both
intravenous and rectal routes of administration
Outcomes Seizure cessation
Seizure recurrence within 24 hours after the presenting seizure had been stopped
Additional drugs needed to control the presenting seizure
Adverse effects
Notes Numerous protocol violators in the study who were then excluded from analysis
The study population was small and there were substantial differences in the size of the
2 treatment groups (lorazepam 33 participants and diazepam 53 participants). There
was an even larger discrepancy in the children who received the drug rectally; rectal
lorazepam (6 children) versus rectal diazepam (19 children)
This clearly suggests a higher violation rate for these children who should have received
rectal lorazepam. This may have been due to clinician uncertainty about the use of rectal
lorazepam, as this drug and route of administration are not used in routine clinical
practice
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “ children were assigned..on an odd
and even dates basis”
Comment: this was done to avoid any
delay incurred by another randomisation
method. The randomisation method may
have contributed to the unequal sizes of the
groups
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Appleton 1995 (Continued)
Allocation concealment (selection bias) High risk As described above, clinicians would be
aware of the allocation by whether the day
was odd or even
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was unblinded, but this would
have been impractical and is not likely to
have affected outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk There were a relatively large number of pro-
tocol violators (16/102 children, or 16% of
the total study population) and these viola-
tors were excluded from the analyses. The
analysis was therefore not an intention-to-
treat analysis
Selective reporting (reporting bias) Low risk All pre-specified outcomeswere reported in
the Results section
Other bias High risk Large discrepancy in the 2 routes of admin-
istration used in the study, probably due to
clinician uncertainty about the use of rec-
tal lorazepam. This discrepancy is likely to
have impacted upon results
Arya 2011
Methods Randomised controlled trial, not blinded
Participants 141 children aged 6 - 14 years attending the emergency room of a hospital in NewDelhi,
India with a seizure, or those having a seizure during attendance
Exclusion criteria: known hypersensitivity to benzodiazepine, child having received any
parenteral anti-epileptic drug within 1 hour of enrolment, presence of severe cardiores-
piratory compromise, presence of cerebrospinal fluid rhinorrhoea and upper respiratory
tract infection sufficiently severe to preclude intranasal administration
58 out of 141 of the children (41%) had generalised tonic-clonic seizures but primary
outcome results are presented separately for the subgroup of generalised tonic-clonic
seizures
Interventions Intranasal versus intravenous lorazepam
Outcomes Cessation of all visible motor activity by 10 minutes
Persistent cessation of seizures by 1 hour
Time to achieve IV access, time from drug administration to stopping of seizure Devel-
opment of hypotension/respiratory depression
Notes Results are presented for the subgroup of 58 children with generalised tonic-clonic
seizures
Inclusion criteria did not include duration of seizure, unlike most of the studies
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Arya 2011 (Continued)
There was 1 protocol violation when intravenous access could not be obtained in 1 child
who was randomised to intravenous lorazepam. This child was treated with intranasal
lorazepam. However the results were analysed on an intention-to-treat basis and no
participants were excluded from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:“ randomisation was done using
blocks of variable length”
Allocation concealment (selection bias) Low risk Quote: “Opaque sealed envelopes contain-
ing allocation of randomisation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was unblinded; this would have
been difficult, due to the different routes
of administration and is not likely to have
affected outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All recruited participants were included in
the analysis and analysed on an intention to
treat basis
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported in
the Results section
Other bias Low risk None identified
Ashrafi 2010
Methods Randomised controlled trial, not blinded and no placebo
Participants 98 children of both sexes and aged 3 months to 12 years attending the emergency
department of two large paediatric hospitals in Tehran, Iran between April 2007 and
April 2008.
Children who already had intravenous access or who were younger than 3 months were
excluded
Interventions Buccal midazolam versus rectal diazepam
Outcomes Cessation of all motor activity within 5 minutes, without respiratory depression and
without seizure recurrence
Treatment initiation time (time spent preparing the drug) and drug effect time (time
from drug administration to seizure cessation) also recorded
Parental satisfaction assessed
Notes Buccal midazolam associated with 100% seizure cessation rate, which is higher than
expected
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Ashrafi 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random number table was used
for randomisation”
Allocation concealment (selection bias) Unclear risk Insufficient information to assess this
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was unblinded; blinding would
have been difficult due to the different
routes used, but
this is unlikely to have had a significant im-
pact on the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk All recruited participants were included in
the analysis
Selective reporting (reporting bias) Low risk All pre-specified outcomeswere reported in
the Results section
Other bias Unclear risk Buccal midazolam associated with 100%
seizure cessation rate, which is higher than
expected.Unclearwhether this high success
rate was due to a particular element of the
trial design
Baysun 2005
Methods Prospective quasi-randomised trial (odd and even days randomisation of the 2 drugs) in
1 centre
Participants 43 children of both sexes aged 2 months to 12 years who presented with a seizure to the
emergency room, regardless of seizure type, aetiology or duration
No exclusion criteria were stated
Interventions Buccal midazolam versus rectal diazepam
Outcomes Cessation of convulsive seizure activity within 10 minutes
Time to seizure cessation
Need for a second drug to control seizures
Presence of adverse events
Notes Children who were seizing on arrival were included, on the assumption that the seizure
was prolonged. This is different frommost of the other studies, which require a period of
seizure activity lasting 5 - 10 minutes before inclusion and randomisation. However, this
should not have introduced bias, as these children should have been equally distributed
between the 2 groups
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Baysun 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Diazepam was given on odd days
of the month and midazolam on the even
days”
Comment: inadequate randomisation
Allocation concealment (selection bias) High risk See above; no concealment of allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible, due to the different
routes of administration of the 2 study
drugs, so this is not likely to have affected
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All recruited participants were included in
the analysis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Low risk None identified
Chamberlain 1997
Methods Prospective randomised study in two centres
Participants 23 children of both sexes and aged birth to 18 years presenting to an emergency depart-
ment with a motor seizure lasting at least 10 minutes
Children who had established intravenous access or who had already received treatment
for this seizure episode were excluded
Interventions Intramuscular midazolam versus intravenous diazepam
Outcomes Seizure cessation within 5 minutes of drug administration
Delayed seizure control defined as cessation of seizures 5 - 10 minutes after drug admin-
istration
Treatment failure, defined as lack of seizure cessation at 10 minutes
Early recurrence, defined as return of seizures within 5 minutes
Recurrence, defined as return of seizures within 60 minutes of drug administration
Presence of respiratory depression
Notes 1 child was enrolled in the study twice, so is represented in both groups. It was not
possible to identify this child in the reported results
There was also a protocol violator who was randomised to receive intravenous diazepam
but received intramuscular midazolam after 25 minutes, due to unsuccessful intravenous
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Chamberlain 1997 (Continued)
access. This participant was excluded from the analysis and would have skewed the results
significantly if he/she had been included. It may have been helpful to know the response
time of this child once treatment was administered, as this is an important example of
the disadvantages of the intravenous route
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patientswere randomly selected by
computer”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Insufficient information to assess this
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blindingwould not have been possible, due
to the different routes of administration of
the 2 study drugs, but this is not likely to
have affected outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote “Three children were randomised
to receive diazepam but were excluded be-
cause their seizures did not persist for 10
minutes.”
Comment: this is unlikely to have made a
significant difference to the analysis
Quote “One child was a protocol devia-
tion and was excluded- was randomised to
diazepam but received midazolam instead
due to unsuccessful attempts at IV access”
Comment: this child should have been in-
cluded in the analysis for it to be considered
an intention-to-treat analysis. However it
would have skewed the results significantly,
as midazolam was not given until after 25
minutes of attempting intravenous access
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias High risk 1 child was enrolled in the study twice, so is
represented in both groups. It was not pos-
sible to identify this child in the reported
results. Due to the small numbers of chil-
dren included in the study, this double-en-
rolment may have impacted on the results
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Chamberlain 2014
Methods Double-blind multicentre randomised trial
Participants 273 patients aged 3 months up to 18 years presenting with convulsive status epilepticus
Interventions intravenous diazepam versus intravenous lorazepam
Outcomes Primary outcomes: Cessation of status epilepticus by 10 minutes without recurrence
within 30 minutes
Requirement for assisted ventilation
Secondary outcomes: Rates of seizure recurrence
Presence of sedation
Times to cessation of status epilepticus
Return to baseline mental status
Notes Consideration was given to sample size with an estimate of 120 participants per group
for 80% power to detect a significant difference between treatments. After an interim
analysis halfway through the study, this was increased to 131 participants per group,
probably because there was less treatment effect difference than anticipated between
the treatment arms. Analysis of data was transparent, with all participants who were
randomised analysed on an intention-to-treat basis but with further per protocol analysis
limited to those with no protocol violation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block randomisation (1:1) with
stratification to 3 age groupswas performed
Allocation concealment (selection bias) Low risk Measures taken to ensure allocation con-
cealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants who were randomised were
analysed on an intention to treat basis. An
additional per protocol analysis limited to
those with <1 no
protocol violation
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Low risk None identified
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Fi gin 2002
Methods Prospective quasi-randomised study (odd and even days randomisation of the 2 drugs)
over 15 months
Participants 45 children of both sexes and aged 1 month to 13 years presenting to the emergency
room with a seizure lasting at least 5 minutes
No exclusion criteria stated
Interventions intranasal midazolam versus rectal diazepam
Outcomes Stopping of seizure within 10 minutes
Time to cessation of seizure
Efficacy of anticonvulsant effect
Need for a second drug to control seizures
Presence of complications
Notes Some methodology described unclear, particularly relating to seizure type and aetiology
of included children. It is therefore unclear if the population of this study is generalisable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Diazepam was given on odd days
of the month and midazolam on the even
days”
Allocation concealment (selection bias) High risk See above; no concealment of allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible, due to the different
routes of administration of the 2 study
drugs, but this is not likely to have affected
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis
Selective reporting (reporting bias) Unclear risk Quote: “information about previous con-
vulsions and history of antiepileptic medi-
cation was obtained..”
Comment: this information was not re-
ported in the Results section but as this is
not one of the primary outcome measures
it is not likely to be significant
Other bias Unclear risk Unclear description of the seizure type and
aetiology of included children, so it is un-
clear if the population of this study is gen-
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Fi gin 2002 (Continued)
eralisable
Gathwala 2012
Methods Randomised controlled trial, unblinded
Participants 120 children aged 6 months to 14 years, attending emergency roomwith an acute seizure
Interventions Intravenous diazepam versus midazolam versus lorazepam
Outcomes Time to seizure cessation
Side effects of drugs: vomiting, apnoea, somnolence, respiratory depression and require-
ment for mechanical ventilation
Number of participants with seizure recurrence, requiring a second dose of medication
or with uncontrolled seizures
Time to seizure recurrence
Notes Unclear exactly when participants were given second dose of drug (range 5 - 20 minutes)
; the convention would be to wait 10 minutes.
Large number with prolonged seizures
The differences in underlying causes may affect applicability to western populations
Seizure cessation is defined as “Cessation of visible epileptic phenomenon or return of
purposeful response to external stimuli within 15 minutes of drug administration”. This
definition is different from all other included studies and latter part of this definition is
not an appropriate criterion for judging seizure cessation, as most individuals following a
tonic-clonic seizure will have a post-ictal phase in which they do not respond to external
stimuli
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by shuffling of envelopes
Allocation concealment (selection bias) Low risk Allocation by sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study was unblinded, but this is not likely to
have affected outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The 3 excluded participants where IV access
was not possible were not included in the
analysis. However, as all routes were intra-
venous this is unlikely to have introducedbias
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
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Gathwala 2012 (Continued)
Other bias High risk The definition of the ’Seizure Cessation’ out-
come used is different from all other included
studies and is not an appropriate criterion for
judging seizure cessation. This definition is
likely to have impacted upon results
Javadzadeh 2012
Methods Randomised unblinded study
Participants 60 children aged 2 months to 15 years old presenting to emergency department with
acute seizure episode
Interventions Intranasal midazolam versus intravenous diazepam
Outcomes Time needed to control seizure
Oxygen saturation and heart rate before and after treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study was unblinded, but this is not likely to have af-
fected outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the analysis and anal-
ysed on an intention-to-treat basis
Selective reporting (reporting bias) High risk Number of childrenwith seizure cessation not reported;
we would expect this outcome to be reported
Other bias Low risk None identified
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Lahat 2000
Methods 12-month randomised controlled trial
Participants 44 children of both sexes and aged 6 months to 5 years presenting to a paediatric
emergency department with a febrile seizure
Children with established intravenous lines or those who had received anticonvulsants
before admission were excluded
Interventions Intravenous diazepam versus intranasal midazolam
Outcomes Seizure cessation
Time to seizure cessation
Incidence of cardiorespiratory distress
Notes In addition this study evaluated a specific subgroup of childrenwith prolonged convulsive
febrile seizures. This is important, as the aetiology of seizures varies across the age ranges
during childhood, thereby potentially affecting results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation was performed in ad-
vance with a random number table by a hos-
pital pharmacist not involved in the study“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: ”and treatment allocations were sealed
in opaque envelopes. Investigators were blind
to these allocations
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was unblinded-;blinding would
have been difficult, due to the different routes
of administration. This is not likely to have af-
fected outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were available for all partici-
pants enrolled in the study
Selective reporting (reporting bias) Unclear risk All prespecified outcomes were reported in the
Results section. In theMethods section, seizure
cessation was defined as ’successful’ if seizures
stopped in < 5minutes, ’successful but delayed’
if seizures stopped after 5 - 10 minutes and
’failure’ if seizures had not stopped after 10
minutes.However, results seem to be presented
only in terms of treatment success and failure.
It is unclear if this is selective reporting of re-
sults
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Lahat 2000 (Continued)
Other bias Low risk None identified
Mahmoudian 2004
Methods Prospective randomised study in 1 centre
Participants 70 children of both sexes and aged 2 months to 15 years presenting with an acute seizure
to the emergency department.
Children who had received anticonvulsants before admission were excluded
Interventions intranasal midazolam versus intravenous diazepam
Outcomes Time from drug treatment to seizure cessation (Treatment successful if seizures stopped
within 10 minutes)
Notes Both treatment arms showed a 100% seizure cessation rate, which is higher than expected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed in
advance with an odd and even number ta-
ble”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “treatment allocations were sealed
in opaque envelopes”
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible, due to the different
routes of administration of the 2 study
drugs, but this is not likely to have affected
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the analy-
sis
Selective reporting (reporting bias) High risk Time taken to insert intravenous cannula
in the intravenous diazepam group should
have been included, as this would have a
significant effect on the time from arrival to
seizure cessation. Other studies comparing
intravenouswith other routes have included
this information
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Mahmoudian 2004 (Continued)
Other bias Unclear risk Both treatment arms showed a 100%
seizure cessation rate, which is higher than
expected. Unclear whether this high success
rate was due to a particular element of the
trial design
McIntyre 2005
Methods Multicentre randomised controlled trial over 3 years 4 months. Randomisation of 2
drugs in weekly blocks
Participants 177 children of both sexes aged 6 months to 16 years presenting to a children’s accident
and emergency department with active generalised tonic-clonic seizures including estab-
lished convulsive status epilepticus
Children with partial seizures or non-convulsive status epilepticus were excluded
Interventions Buccal midazolam versus rectal diazepam
Outcomes Seizure cessation without recurrence within 1 hour and without respiratory depression
Notes 219 convulsive episodes were recorded in the 177 children. Some results are reported
only as the number of episodes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “ weekly blocks of treatment were
randomly selected for each of the four cen-
tres. The randomisation sequence was gen-
erated ...from a table of random numbers”
Comment: probably done
Allocation concealment (selection bias) High risk Quote: “Allocationwas not concealed from
attending staff ”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible, due to the different
routes of administration of the 2 study
drugs
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “46 episodes were excluded”. 46
episodes were screened for eligibility but
did not meet criteria; all participants were
included in the analysis
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McIntyre 2005 (Continued)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Unclear risk None identified
Momen 2015
Methods Unblinded randomised trial
Participants 100 children with convulsive status epilepticus aged 1 month to 16 years
Interventions Intramuscular midazolam versus rectal diazepam
Outcomes Seizure cessation after drug administration without recurrence within 60 minutes
Respiratory rate and blood pressure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table
Allocation concealment (selection bias) High risk No allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Studywas unblinded, but this is not likely to have affected
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participantswere included in the analysis and analysed
on an intention-to-treat basis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in the Results
section
Other bias Unclear risk None identified
Mpimbaza 2008
Methods Placebo-controlled single-blinded randomised study in 1 centre
Participants 330 children of both sexes and aged 3months to 12 years who presented while convulsing
or experienced a seizure lasting > 5 minutes to an emergency department in Uganda.
Note 67.3% of children had malaria and 13.7% had cerebral malaria
Children aged less than 3 months or more than 12 years, who had evidence of prior
treatment or whose convulsion stopped prior to treatment were excluded
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Mpimbaza 2008 (Continued)
Interventions Buccal midazolam versus rectal diazepam
Outcomes Cessation of visible seizure activity within 10 minutes, without recurrence in the sub-
sequent hour Convulsion lasting > 10 minutes or recurring within 1 hour, defined as
treatment failures Time to cessation of convulsions
Seizure recurrence in first hour or within subsequent 24 hours, time to seizure recurrence
Presence of respiratory depression
Notes Study conducted in Africa with a high proportion of children with either cerebral malaria
or meningitis. Consequently, not readily generalisable to western populations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a computer was used to generate a
list of sequential random treatment codes”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “each treatment code ... placed in a
opaque envelope, sealed. Investigators were
not aware of a patient’s treatment alloca-
tion”
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote; “Study drugs and placebo were pre-
packagedby a pharmacist not involvedwith
patient care. ”
Comment: probably done
Quote: “Although the study team were
not aware which treatment a patient re-
ceived they were aware of the treatment
code, therefore we considered this single-
blinded”
Comment: blinding probably adequate as
each participant received placebo and study
drug
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data analysed on an intention to treat basis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias High risk A high proportion of the children recruited
had either cerebral malaria or meningitis.
These co-morbidities may have impacted
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Mpimbaza 2008 (Continued)
upon the results
Shah 2005
Methods Partly-randomised prospective trial in a single centre over 1 year
Participants 115 children of both sexes aged 1 month to 12 years either presenting to the emergency
departmentwith acute convulsions or who developed acute seizures on the ward or PICU
Those who had already had treatment for the seizure were excluded
Interventions intramuscular midazolam versus intravenous diazepam
Outcomes Mean time from administration of drug to cessation of seizures
Adverse events such as thrombophlebitis
Notes Not all participants were randomised; only those who were randomised are included in
the results of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients who already had an intra-
venous access present were treated with in-
travenous diazepam.. patients without an
intravenous access were randomised into 2
groups”
Comment: randomisation is inadequate, as
treatment determined by presence of IV ac-
cess whichmay introduce bias (patients not
randomised are not included in the review)
Method of randomisation of those without
an IV access is unclear
Allocation concealment (selection bias) High risk No information about whether allocation
in those without an IV access was con-
cealed. Allocation definitely not concealed
in those with an intravenous access
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible due to the different
routes of administration of the 2 study
drugs, but this is not likely to have affected
outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis
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Shah 2005 (Continued)
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Low risk None identified
Sreenath 2010
Methods Randomised prospective trial in a single centre
Participants 178 children of both sexes aged 1 - 12 years presenting with convulsive status epilepticus
(continuous convulsive activity for 5 minutes or more).
Exclusion criteria were treatment with any anti-epileptic medication in preceding 4
weeks, acute head trauma, history of poisoning and jaundice, suspected renal failure or
diarrhoea presenting with seizures
Interventions intravenous lorazepam versus intravenous diazepam-phenytoin combination
Outcomes Cessation of seizure activity within 10 minutes and no recurrence over the subsequent
18 hours
Time to seizure cessation
Number of doses of study drug required to stop convulsions
Use of additional anti-epileptic drugs
Total number of seizures in first 18 hours following administration of study drug
Presence of respiratory depression
Requirement for PICU transfer for mechanical ventilation
Requirement to cross over to alternative regimen due to ongoing seizures
Notes One child received lorazepam despite being randomised to diazepam-phenytoin. This
led to a difference in the number of participants in each group
The study protocol states that where access could not be obtained, rectal lorazepam
or diazepam would be used instead. The number of participants receiving rectal drugs
should have been included in the paper,-but was clarified through personal communi-
cation with the author who informed us that all drugs were given intravenously
Both treatment arms showed a 100% seizure cessation rate, which is higher than expected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Simple randomisation was done
using a computer generated random num-
ber table”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “Allocation was by sealed envelope
technique”
Comment: probably done
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Sreenath 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was unblinded but this is un-
likely to have had a significant impact on
the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis. One received lorazepam despite be-
ing randomised to diazepam-phenytoin, i.
e. was a protocol violation. Data were anal-
ysed on intention-to-treat basis. This is un-
likely to have had a significant impact on
the overall findings of the study
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Unclear risk Both treatment arms showed a 100%
seizure cessation rate, which is higher than
expected. Unclear whether this high suc-
cess rate was due to a particular element of
the trial design
Talukdar 2009
Methods Prospective randomised trial in a single centre
Participants 120 children of both sexes aged 0 - 12 years (mean age 3.2 years) presenting with an
episode of convulsion, irrespective of cause and duration.
Those patients with myoclonic, absence and atonic seizures were excluded
Interventions Buccal midazolam versus intravenous diazepam
Outcomes Cessation of all motor activity within or by 5 minutes of administration of the drug
Treatment initiation time (time from noting seizure to drug administration), drug effect
time (time from drug administration to effect) and total controlling time, a combination
of the previous two
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was done using the
random number table”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Insufficient information to assess this
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Talukdar 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study unblinded, but blinding would not
have been possible due to the different
routes of administration of the 2 study
drugs; this is not likely to have affected out-
come
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the Results section
Other bias Low risk None identified
IV: intravenous
PICU: paediatric intensive care unit
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agarwal 2007 Only 38 of 100 participants in this study were under 16 years of age. In addition, this study examined the
treatment of benzodiazepine-refractory status epilepticus, whereas we are concerned with the treatment of
children presenting with acute convulsive status epilepticus
Arpita 2014 This study examined the management of refractory not acute status epilepticus
Bhattacharyya 2006 Most seizures were simple partial seizures as opposed to generalised tonic-clonic seizures. Study also included
children with absence, myoclonic and atonic seizures
Camfield 1980 The study examined drug management for the long-term prevention of recurring febrile seizures, rather than
management of acute convulsions
Cereghino 1998 This study examined diazepam treatment for clusters of seizures rather than acute convulsions
Heckmatt 1976 The study examined drug management for the long-term prevention of recurring febrile seizures, rather than
management of acute convulsions
Holsti 2010 This study compared intranasal midazolam and rectal diazepam for the treatment of seizures at home, not in
a hospital-based setting, so did not meet our inclusion criteria
Kutlu 2003 This was a study of the use of buccal midazolam for acute seizures in children, but without any comparison
or placebo group
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(Continued)
Mahmoudian 2006 This study examined the treatment of children already treated with IV diazepam, phenytoin and phenobarbital
and whose seizures had lasted at least 60 minutes. The comparison was between rectal sodium valproate
and intravenous midazolam. We excluded this study as it was examining the treatment of refractory status
epilepticus
McCormick 1999 This study was a prospective comparison of intravenous midazolam and lorazepam in 27 paediatric patients.
However this was only published in abstract form as conference proceedings, so there was insufficient infor-
mation on which to base assessment of the trial. Attempts to contact the authors were unsuccessful
Mehta 2007 This study included children with refractory status epilepticus who were initially treated with intravenous
diazepam and 2 doses of intravenous phenytoin, then randomised to either IV SVA or diazepam infusion. We
excluded this study as it was examining the management of refractory not acute status epilepticus
Mittal 2014 This study examined the management of refractory not acute status epilepticus
Morton 2007 This was a study of the use of intravenous valproate for acute seizures in children, but without any comparison
or placebo group
Qureshi 2002 This was excluded as it was a retrospective audit of practice, comparing two different time periods when
different seizure protocols were used. It did not meet our inclusion criteria of being a randomised, quasi-
randomised or controlled study
Rosati 2016 This study examined the management of refractory not acute status epilepticus
Scott 1999 Quasi randomised study of rectal diazepam and buccal midazolam in treating 79 seizure episodes in 18 patients
with severe and refractory epilepsy in a residential institution. The study does not make clear how many of
the 11 paediatric patients had experienced a tonic-clonic and not a complex partial or myoclonic seizure when
treated with diazepam or midazolam. Only 11 of the 18 patients were aged 16 years or under
Silbergleit 2012 This double-blind, randomised study compared intramuscular midazolam with intravenous lorazepam for the
pre-hospital treatment of status epilepticus in children and adults. As the study did not take place in a hospital
setting it did not meet our inclusion criteria
Singhi 2002 This study compared continuousmidazolamor diazepam infusion in patients with refractory status epilepticus,
defined as motor seizures uncontrolled after two doses of diazepam and a phenytoin infusion. We excluded
this study as it concerned the management of refractory not acute status epilepticus
Strengell 2009 The study examined drug management for the long-term prevention of recurring febrile seizures, rather than
management of acute convulsions
Tonekaboni 2012 Less than 70% of participants had generalised tonic-clonic seizures. We contacted the authors to request
subgroup data but these were not supplied
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D A T A A N D A N A L Y S E S
Comparison 1. Lorazepam versus diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 3 439 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.98, 1.20]
1.1 Intravenous 3 414 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.16]
1.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [1.47, 5.55]
2 Time from drug administration
to stopping of seizures
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Intravenous 1 80 Mean Difference (IV, Fixed, 95% CI) 6.18 [-7.83, 20.19]
3 Incidence of respiratory
depression
3 439 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.55, 0.93]
3.1 Intravenous 3 414 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.55, 0.92]
3.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.04, 20.78]
4 Additional dose of the trial drug
required to stop seizures
3 439 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.64, 1.20]
4.1 Intravenous 3 414 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.71, 1.33]
4.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.56]
5 Additional drugs required to
stop seizures
2 359 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.45, 1.24]
5.1 Intravenous 2 334 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.54, 1.55]
5.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.69]
6 Seizure recurrence within 24
hours
3 439 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.61, 1.20]
6.1 Intravenous 3 414 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.65, 1.27]
6.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 2.92]
7 Incidence of admissions to the
intensive care unit (ICU)
1 86 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 0.98]
7.1 Intravenous 1 61 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.22]
7.2 Rectal 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.03, 10.51]
Comparison 2. Intranasal lorazepam versus intramuscular paraldehyde
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Within 10 minutes 1 160 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.99, 1.52]
2 Additional drugs required to
stop seizures
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.18, 0.81]
3 Seizure recurrence within 24
hours
1 160 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.31, 1.71]
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Comparison 3. Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin combination
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Within 10 minutes 1 178 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.98, 1.02]
2 Incidence of respiratory
depression
1 178 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.22, 2.82]
3 Additional drugs required to
stop seizures
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 More than one dose of the
trial drug required
1 178 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.17, 1.04]
Comparison 4. Intravenous lorazepam versus intranasal lorazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Within 10 minutes 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.77, 1.49]
1.2 Within 1 hour 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.43, 1.17]
Comparison 5. Buccal midazolam versus rectal diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 4 690 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.13, 1.38]
1.1 Within 5 minutes 1 98 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.07, 1.40]
1.2 Within 10 minutes 2 373 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.95, 1.21]
1.3 Within one hour 1 219 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [1.45, 2.91]
2 Incidence of respiratory
depression
4 690 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.61, 1.25]
3 Additional drugs required to
stop seizures
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Intravenous lorazepam
required
1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.42, 0.79]
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Comparison 6. Buccal midazolam versus intravenous diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation within five
minutes
1 120 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.80, 1.03]
2 Time from drug administration
to stopping of seizures
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Treatment initiation time
(minutes)
1 120 Mean Difference (IV, Fixed, 95% CI) -1.09 [-1.31, -0.87]
2.2 Time for drug effect
(minutes)
1 120 Mean Difference (IV, Fixed, 95% CI) 0.56 [0.29, 0.83]
2.3 Total time to seizure
cessation (minutes)
1 120 Mean Difference (IV, Fixed, 95% CI) -0.59 [-0.96, -0.22]
Comparison 7. Intranasal midazolam versus intravenous diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure Cessation 2 122 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.91, 1.06]
2 Time from drug administration
to stopping of seizures
[minutes]
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Treatment initiation time
(minutes)
1 52 Mean Difference (IV, Fixed, 95% CI) -2.0 [-3.03, -0.97]
2.2 Time for drug effect
(minutes)
2 122 Mean Difference (IV, Fixed, 95% CI) 0.62 [-0.14, 1.38]
2.3 Total time to seizure
cessation (minutes)
2 112 Mean Difference (IV, Fixed, 95% CI) 0.80 [0.24, 1.35]
Comparison 8. Intranasal midazolam versus rectal diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Within 10 minutes 1 45 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.00, 2.16]
2 Additional drugs required to
stop seizures
1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.10, 1.03]
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Comparison 9. Intramuscular midazolam versus intravenous diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 2 105 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.09]
2 Time from drug administration
to stopping of seizures
(minutes)
2 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 Treatment initiation time
(minutes)
1 24 Mean Difference (Fixed, 95% CI) -4.5 [-6.68, -2.32]
2.2 Time for drug effect
(minutes)
1 24 Mean Difference (Fixed, 95% CI) 1.1 [-0.91, 3.11]
2.3 Total time to seizure
cessation (minutes)
2 105 Mean Difference (Fixed, 95% CI) -2.68 [-3.94, -1.42]
3 Additional drugs required to
stop seizures
2 105 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.35, 5.13]
4 Seizure recurrence within 24
hours
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Within 15 minutes 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.06, 12.01]
4.2 Within one hour 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.62]
Comparison 10. Intramuscular midazolam versus rectal diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Within 1 hour 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.93, 1.12]
Comparison 11. Intravenous midazolam versus intravenous diazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 80 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.97, 1.21]
2 Time from drug administration
to stopping of seizures
1 80 Mean Difference (IV, Fixed, 95% CI) 7.68 [-6.73, 22.09]
3 Incidence of respiratory
depression
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.95]
4 Additional dose of the trial drug
required to stop seizures
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.14]
5 Seizure recurrence within 24
hours
1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.58]
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Comparison 12. Intravenous midazolam versus intravenous lorazepam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seizure cessation 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.91, 1.04]
2 Time from drug administration
to stopping of seizures
1 80 Mean Difference (IV, Fixed, 95% CI) 1.5 [-9.37, 12.37]
3 Additional dose of the trial drug
required to stop seizures
1 80 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 71.51]
4 Seizure recurrence within 24
hours
1 80 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.15, 6.76]
Analysis 1.1. Comparison 1 Lorazepam versus diazepam, Outcome 1 Seizure cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 1 Seizure cessation
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 19/27 22/34 12.3 % 1.09 [ 0.77, 1.54 ]
Chamberlain 2014 97/133 101/140 62.4 % 1.01 [ 0.87, 1.17 ]
Gathwala 2012 40/40 36/40 23.1 % 1.11 [ 0.99, 1.24 ]
Subtotal (95% CI) 200 214 97.9 % 1.04 [ 0.94, 1.16 ]
Total events: 156 (Lorazepam), 159 (Diazepam)
Heterogeneity: Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
2 Rectal
Appleton 1995 6/6 6/19 2.1 % 2.86 [ 1.47, 5.55 ]
Subtotal (95% CI) 6 19 2.1 % 2.86 [ 1.47, 5.55 ]
Total events: 6 (Lorazepam), 6 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0019)
Total (95% CI) 206 233 100.0 % 1.08 [ 0.98, 1.20 ]
Total events: 162 (Lorazepam), 165 (Diazepam)
Heterogeneity: Chi2 = 9.23, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 8.61, df = 1 (P = 0.00), I2 =88%
0.1 0.2 0.5 1 2 5 10
Favours Diazepam Favours Lorazepam
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Analysis 1.2. Comparison 1 Lorazepam versus diazepam, Outcome 2 Time from drug administration to
stopping of seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 2 Time from drug administration to stopping of seizures
Study or subgroup Lorazepam Diazepam
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Seconds] N Mean(SD)[Seconds] IV,Fixed,95% CI IV,Fixed,95% CI
1 Intravenous
Gathwala 2012 40 91.12 (23.58) 40 84.94 (38.56) 100.0 % 6.18 [ -7.83, 20.19 ]
Subtotal (95% CI) 40 40 100.0 % 6.18 [ -7.83, 20.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
-100 -50 0 50 100
Favours Lorazepam Favours Diazepam
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Analysis 1.3. Comparison 1 Lorazepam versus diazepam, Outcome 3 Incidence of respiratory depression.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 3 Incidence of respiratory depression
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 1/27 7/34 7.7 % 0.18 [ 0.02, 1.37 ]
Chamberlain 2014 54/133 74/140 89.5 % 0.77 [ 0.59, 0.99 ]
Gathwala 2012 0/40 1/40 1.9 % 0.33 [ 0.01, 7.95 ]
Subtotal (95% CI) 200 214 99.0 % 0.71 [ 0.55, 0.92 ]
Total events: 55 (Lorazepam), 82 (Diazepam)
Heterogeneity: Chi2 = 2.29, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 2.56 (P = 0.011)
2 Rectal
Appleton 1995 0/6 1/19 1.0 % 0.95 [ 0.04, 20.78 ]
Subtotal (95% CI) 6 19 1.0 % 0.95 [ 0.04, 20.78 ]
Total events: 0 (Lorazepam), 1 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 206 233 100.0 % 0.72 [ 0.55, 0.93 ]
Total events: 55 (Lorazepam), 83 (Diazepam)
Heterogeneity: Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
0.005 0.1 1 10 200
Favours Lorazepam Favours Diazepam
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Analysis 1.4. Comparison 1 Lorazepam versus diazepam, Outcome 4 Additional dose of the trial drug
required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 4 Additional dose of the trial drug required to stop seizures
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 8/27 12/34 16.8 % 0.84 [ 0.40, 1.76 ]
Chamberlain 2014 44/133 42/140 64.9 % 1.10 [ 0.78, 1.56 ]
Gathwala 2012 0/40 4/40 7.1 % 0.11 [ 0.01, 2.00 ]
Subtotal (95% CI) 200 214 88.9 % 0.97 [ 0.71, 1.33 ]
Total events: 52 (Lorazepam), 58 (Diazepam)
Heterogeneity: Chi2 = 2.81, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Rectal
Appleton 1995 0/6 13/19 11.1 % 0.11 [ 0.01, 1.56 ]
Subtotal (95% CI) 6 19 11.1 % 0.11 [ 0.01, 1.56 ]
Total events: 0 (Lorazepam), 13 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 206 233 100.0 % 0.88 [ 0.64, 1.20 ]
Total events: 52 (Lorazepam), 71 (Diazepam)
Heterogeneity: Chi2 = 6.00, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 2.58, df = 1 (P = 0.11), I2 =61%
0.005 0.1 1 10 200
Favours Lorazepam Favours Diazepam
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Analysis 1.5. Comparison 1 Lorazepam versus diazepam, Outcome 5 Additional drugs required to stop
seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 5 Additional drugs required to stop seizures
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 1/27 5/34 14.1 % 0.25 [ 0.03, 2.03 ]
Chamberlain 2014 21/133 21/140 65.2 % 1.05 [ 0.60, 1.84 ]
Subtotal (95% CI) 160 174 79.3 % 0.91 [ 0.54, 1.55 ]
Total events: 22 (Lorazepam), 26 (Diazepam)
Heterogeneity: Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Rectal
Appleton 1995 0/6 12/19 20.7 % 0.11 [ 0.01, 1.69 ]
Subtotal (95% CI) 6 19 20.7 % 0.11 [ 0.01, 1.69 ]
Total events: 0 (Lorazepam), 12 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 166 193 100.0 % 0.75 [ 0.45, 1.24 ]
Total events: 22 (Lorazepam), 38 (Diazepam)
Heterogeneity: Chi2 = 4.38, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 2.20, df = 1 (P = 0.14), I2 =54%
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Analysis 1.6. Comparison 1 Lorazepam versus diazepam, Outcome 6 Seizure recurrence within 24 hours.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 6 Seizure recurrence within 24 hours
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 6/27 12/34 18.8 % 0.63 [ 0.27, 1.46 ]
Chamberlain 2014 38/133 39/140 67.2 % 1.03 [ 0.70, 1.50 ]
Gathwala 2012 2/40 4/40 7.1 % 0.50 [ 0.10, 2.58 ]
Subtotal (95% CI) 200 214 93.1 % 0.91 [ 0.65, 1.27 ]
Total events: 46 (Lorazepam), 55 (Diazepam)
Heterogeneity: Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Rectal
Appleton 1995 0/6 7/19 6.9 % 0.19 [ 0.01, 2.92 ]
Subtotal (95% CI) 6 19 6.9 % 0.19 [ 0.01, 2.92 ]
Total events: 0 (Lorazepam), 7 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 206 233 100.0 % 0.86 [ 0.61, 1.20 ]
Total events: 46 (Lorazepam), 62 (Diazepam)
Heterogeneity: Chi2 = 2.97, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.23, df = 1 (P = 0.27), I2 =19%
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Analysis 1.7. Comparison 1 Lorazepam versus diazepam, Outcome 7 Incidence of admissions to the
intensive care unit (ICU).
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 1 Lorazepam versus diazepam
Outcome: 7 Incidence of admissions to the intensive care unit (ICU)
Study or subgroup Lorazepam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous
Appleton 1995 0/27 8/34 85.4 % 0.07 [ 0.00, 1.22 ]
Subtotal (95% CI) 27 34 85.4 % 0.07 [ 0.00, 1.22 ]
Total events: 0 (Lorazepam), 8 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Rectal
Appleton 1995 0/6 2/19 14.6 % 0.57 [ 0.03, 10.51 ]
Subtotal (95% CI) 6 19 14.6 % 0.57 [ 0.03, 10.51 ]
Total events: 0 (Lorazepam), 2 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Total (95% CI) 33 53 100.0 % 0.15 [ 0.02, 0.98 ]
Total events: 0 (Lorazepam), 10 (Diazepam)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
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Analysis 2.1. Comparison 2 Intranasal lorazepam versus intramuscular paraldehyde, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 2 Intranasal lorazepam versus intramuscular paraldehyde
Outcome: 1 Seizure cessation
Study or subgroup Lorazepam Paraldehyde Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 10 minutes
Ahmad 2006 60/80 49/80 100.0 % 1.22 [ 0.99, 1.52 ]
Subtotal (95% CI) 80 80 100.0 % 1.22 [ 0.99, 1.52 ]
Total events: 60 (Lorazepam), 49 (Paraldehyde)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
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Analysis 2.2. Comparison 2 Intranasal lorazepam versus intramuscular paraldehyde, Outcome 2 Additional
drugs required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 2 Intranasal lorazepam versus intramuscular paraldehyde
Outcome: 2 Additional drugs required to stop seizures
Study or subgroup Lorazepam Paraldehyde Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmad 2006 8/80 21/80 100.0 % 0.38 [ 0.18, 0.81 ]
Total (95% CI) 80 80 100.0 % 0.38 [ 0.18, 0.81 ]
Total events: 8 (Lorazepam), 21 (Paraldehyde)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Intranasal lorazepam versus intramuscular paraldehyde, Outcome 3 Seizure
recurrence within 24 hours.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 2 Intranasal lorazepam versus intramuscular paraldehyde
Outcome: 3 Seizure recurrence within 24 hours
Study or subgroup Lorazepam Paraldehyde Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmad 2006 8/80 11/80 100.0 % 0.73 [ 0.31, 1.71 ]
Total (95% CI) 80 80 100.0 % 0.73 [ 0.31, 1.71 ]
Total events: 8 (Lorazepam), 11 (Paraldehyde)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin
combination, Outcome 1 Seizure cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin combination
Outcome: 1 Seizure cessation
Study or subgroup Lorazepam
Diazepam /
Phenytoin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 10 minutes
Sreenath 2010 90/90 88/88 100.0 % 1.00 [ 0.98, 1.02 ]
Subtotal (95% CI) 90 88 100.0 % 1.00 [ 0.98, 1.02 ]
Total events: 90 (Lorazepam), 88 (Diazepam / Phenytoin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.2. Comparison 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin
combination, Outcome 2 Incidence of respiratory depression.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin combination
Outcome: 2 Incidence of respiratory depression
Study or subgroup Lorazepam Diazepam/Phenytoin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sreenath 2010 4/90 5/88 100.0 % 0.78 [ 0.22, 2.82 ]
Total (95% CI) 90 88 100.0 % 0.78 [ 0.22, 2.82 ]
Total events: 4 (Lorazepam), 5 (Diazepam/Phenytoin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin
combination, Outcome 3 Additional drugs required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 3 Intravenous lorazepam versus intravenous diazepam/intravenous phenytoin combination
Outcome: 3 Additional drugs required to stop seizures
Study or subgroup Lorazepam Diazepam/Phenytoin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 More than one dose of the trial drug required
Sreenath 2010 6/90 14/88 100.0 % 0.42 [ 0.17, 1.04 ]
Subtotal (95% CI) 90 88 100.0 % 0.42 [ 0.17, 1.04 ]
Total events: 6 (Lorazepam), 14 (Diazepam/Phenytoin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
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Analysis 4.1. Comparison 4 Intravenous lorazepam versus intranasal lorazepam, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 4 Intravenous lorazepam versus intranasal lorazepam
Outcome: 1 Seizure cessation
Study or subgroup
Intravenous
lorazepam Intranasal lorazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 10 minutes
Arya 2011 26/35 16/23 100.0 % 1.07 [ 0.77, 1.49 ]
Subtotal (95% CI) 35 23 100.0 % 1.07 [ 0.77, 1.49 ]
Total events: 26 (Intravenous lorazepam), 16 (Intranasal lorazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 Within 1 hour
Arya 2011 15/35 14/23 100.0 % 0.70 [ 0.43, 1.17 ]
Subtotal (95% CI) 35 23 100.0 % 0.70 [ 0.43, 1.17 ]
Total events: 15 (Intravenous lorazepam), 14 (Intranasal lorazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 5.1. Comparison 5 Buccal midazolam versus rectal diazepam, Outcome 1 Seizure cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 5 Buccal midazolam versus rectal diazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 5 minutes
Ashrafi 2010 49/49 40/49 20.0 % 1.22 [ 1.07, 1.40 ]
Subtotal (95% CI) 49 49 20.0 % 1.22 [ 1.07, 1.40 ]
Total events: 49 (Midazolam), 40 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
2 Within 10 minutes
Baysun 2005 18/23 17/20 9.0 % 0.92 [ 0.69, 1.22 ]
Mpimbaza 2008 125/165 114/165 56.3 % 1.10 [ 0.96, 1.25 ]
Subtotal (95% CI) 188 185 65.3 % 1.07 [ 0.95, 1.21 ]
Total events: 143 (Midazolam), 131 (Diazepam)
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Within one hour
McIntyre 2005 61/109 30/110 14.7 % 2.05 [ 1.45, 2.91 ]
Subtotal (95% CI) 109 110 14.7 % 2.05 [ 1.45, 2.91 ]
Total events: 61 (Midazolam), 30 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P = 0.000051)
Total (95% CI) 346 344 100.0 % 1.25 [ 1.13, 1.38 ]
Total events: 253 (Midazolam), 201 (Diazepam)
Heterogeneity: Chi2 = 15.91, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Chi2 = 12.35, df = 2 (P = 0.00), I2 =84%
0.5 0.7 1 1.5 2
Favours Diazepam Favours Midazolam
96Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Buccal midazolam versus rectal diazepam, Outcome 2 Incidence of respiratory
depression.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 5 Buccal midazolam versus rectal diazepam
Outcome: 2 Incidence of respiratory depression
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashrafi 2010 0/49 0/49 Not estimable
Mpimbaza 2008 2/165 2/165 7.4 % 1.00 [ 0.14, 7.01 ]
McIntyre 2005 5/109 7/110 25.7 % 0.72 [ 0.24, 2.20 ]
Baysun 2005 18/23 17/20 67.0 % 0.92 [ 0.69, 1.22 ]
Total (95% CI) 346 344 100.0 % 0.88 [ 0.61, 1.25 ]
Total events: 25 (Midazolam), 26 (Diazepam)
Heterogeneity: Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Buccal midazolam versus rectal diazepam, Outcome 3 Additional drugs
required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 5 Buccal midazolam versus rectal diazepam
Outcome: 3 Additional drugs required to stop seizures
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous lorazepam required
McIntyre 2005 36/109 63/110 100.0 % 0.58 [ 0.42, 0.79 ]
Subtotal (95% CI) 109 110 100.0 % 0.58 [ 0.42, 0.79 ]
Total events: 36 (Midazolam), 63 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00055)
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Analysis 6.1. Comparison 6 Buccal midazolam versus intravenous diazepam, Outcome 1 Seizure cessation
within five minutes.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 6 Buccal midazolam versus intravenous diazepam
Outcome: 1 Seizure cessation within five minutes
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Talukdar 2009 51/60 56/60 100.0 % 0.91 [ 0.80, 1.03 ]
Total (95% CI) 60 60 100.0 % 0.91 [ 0.80, 1.03 ]
Total events: 51 (Midazolam), 56 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Buccal midazolam versus intravenous diazepam, Outcome 2 Time from drug
administration to stopping of seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 6 Buccal midazolam versus intravenous diazepam
Outcome: 2 Time from drug administration to stopping of seizures
Study or subgroup Midazolam Diazepam
Mean
Difference Weight
Mean
Difference
N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Fixed,95% CI IV,Fixed,95% CI
1 Treatment initiation time (minutes)
Talukdar 2009 60 0.9733 (0.23) 60 2.07 (0.841) 100.0 % -1.09 [ -1.31, -0.87 ]
Subtotal (95% CI) 60 60 100.0 % -1.09 [ -1.31, -0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.72 (P < 0.00001)
2 Time for drug effect (minutes)
Talukdar 2009 60 1.6902 (0.93) 60 1.13 (0.5) 100.0 % 0.56 [ 0.29, 0.83 ]
Subtotal (95% CI) 60 60 100.0 % 0.56 [ 0.29, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000040)
3 Total time to seizure cessation (minutes)
Talukdar 2009 60 2.3922 (1.04) 60 2.98 (1.01) 100.0 % -0.59 [ -0.96, -0.22 ]
Subtotal (95% CI) 60 60 100.0 % -0.59 [ -0.96, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
-1 -0.5 0 0.5 1
Favours Midazolam Favours Diazepam
99Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.1. Comparison 7 Intranasal midazolam versus intravenous diazepam, Outcome 1 Seizure
Cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 7 Intranasal midazolam versus intravenous diazepam
Outcome: 1 Seizure Cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lahat 2000 23/26 24/26 40.3 % 0.96 [ 0.80, 1.14 ]
Mahmoudian 2004 35/35 35/35 59.7 % 1.00 [ 0.95, 1.06 ]
Total (95% CI) 61 61 100.0 % 0.98 [ 0.91, 1.06 ]
Total events: 58 (Midazolam), 59 (Diazepam)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Intranasal midazolam versus intravenous diazepam, Outcome 2 Time from
drug administration to stopping of seizures [minutes].
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 7 Intranasal midazolam versus intravenous diazepam
Outcome: 2 Time from drug administration to stopping of seizures [minutes]
Study or subgroup Midazolam Diazepam
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Treatment initiation time (minutes)
Lahat 2000 26 3.5 (1.8) 26 5.5 (2) 100.0 % -2.00 [ -3.03, -0.97 ]
Subtotal (95% CI) 26 26 100.0 % -2.00 [ -3.03, -0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
2 Time for drug effect (minutes)
Lahat 2000 26 3.1 (2.2) 26 2.5 (1.9) 46.0 % 0.60 [ -0.52, 1.72 ]
Mahmoudian 2004 35 3.58 (1.68) 35 2.94 (2.62) 54.0 % 0.64 [ -0.39, 1.67 ]
Subtotal (95% CI) 61 61 100.0 % 0.62 [ -0.14, 1.38 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
3 Total time to seizure cessation (minutes)
Javadzadeh 2012 30 3.16 (1.24) 30 2.16 (1.02) 93.0 % 1.00 [ 0.43, 1.57 ]
Lahat 2000 26 6.1 (3.6) 26 8 (4.1) 7.0 % -1.90 [ -4.00, 0.20 ]
Subtotal (95% CI) 56 56 100.0 % 0.80 [ 0.24, 1.35 ]
Heterogeneity: Chi2 = 6.83, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.82 (P = 0.0048)
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Analysis 8.1. Comparison 8 Intranasal midazolam versus rectal diazepam, Outcome 1 Seizure cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 8 Intranasal midazolam versus rectal diazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 10 minutes
Fi gin 2002 20/23 13/22 100.0 % 1.47 [ 1.00, 2.16 ]
Subtotal (95% CI) 23 22 100.0 % 1.47 [ 1.00, 2.16 ]
Total events: 20 (Midazolam), 13 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
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Analysis 8.2. Comparison 8 Intranasal midazolam versus rectal diazepam, Outcome 2 Additional drugs
required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 8 Intranasal midazolam versus rectal diazepam
Outcome: 2 Additional drugs required to stop seizures
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fi gin 2002 3/23 9/22 100.0 % 0.32 [ 0.10, 1.03 ]
Total (95% CI) 23 22 100.0 % 0.32 [ 0.10, 1.03 ]
Total events: 3 (Midazolam), 9 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Intramuscular midazolam versus intravenous diazepam, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 9 Intramuscular midazolam versus intravenous diazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chamberlain 1997 12/13 10/11 23.2 % 1.02 [ 0.80, 1.30 ]
Shah 2005 45/50 29/31 76.8 % 0.96 [ 0.84, 1.10 ]
Total (95% CI) 63 42 100.0 % 0.97 [ 0.87, 1.09 ]
Total events: 57 (Midazolam), 39 (Diazepam)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Intramuscular midazolam versus intravenous diazepam, Outcome 2 Time from
drug administration to stopping of seizures (minutes).
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 9 Intramuscular midazolam versus intravenous diazepam
Outcome: 2 Time from drug administration to stopping of seizures (minutes)
Study or subgroup Midazolam Diazepam Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Treatment initiation time (minutes)
Chamberlain 1997 13 11 -4.5 (1.1129) 100.0 % -4.50 [ -6.68, -2.32 ]
Subtotal (95% CI) 13 11 100.0 % -4.50 [ -6.68, -2.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000053)
2 Time for drug effect (minutes)
Chamberlain 1997 13 11 1.1 (1.0276) 100.0 % 1.10 [ -0.91, 3.11 ]
Subtotal (95% CI) 13 11 100.0 % 1.10 [ -0.91, 3.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
3 Total time to seizure cessation (minutes)
Chamberlain 1997 13 11 -3.32 (1.572) 16.7 % -3.32 [ -6.40, -0.24 ]
Shah 2005 50 31 -2.5522 (0.7029) 83.3 % -2.55 [ -3.93, -1.17 ]
Subtotal (95% CI) 63 42 100.0 % -2.68 [ -3.94, -1.42 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000030)
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Analysis 9.3. Comparison 9 Intramuscular midazolam versus intravenous diazepam, Outcome 3 Additional
drugs required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 9 Intramuscular midazolam versus intravenous diazepam
Outcome: 3 Additional drugs required to stop seizures
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chamberlain 1997 1/13 1/11 30.5 % 0.85 [ 0.06, 12.01 ]
Shah 2005 5/50 2/31 69.5 % 1.55 [ 0.32, 7.51 ]
Total (95% CI) 63 42 100.0 % 1.34 [ 0.35, 5.13 ]
Total events: 6 (Midazolam), 3 (Diazepam)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midazolam Favours Diazepam
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Analysis 9.4. Comparison 9 Intramuscular midazolam versus intravenous diazepam, Outcome 4 Seizure
recurrence within 24 hours.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 9 Intramuscular midazolam versus intravenous diazepam
Outcome: 4 Seizure recurrence within 24 hours
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 15 minutes
Chamberlain 1997 1/13 1/11 100.0 % 0.85 [ 0.06, 12.01 ]
Subtotal (95% CI) 13 11 100.0 % 0.85 [ 0.06, 12.01 ]
Total events: 1 (Midazolam), 1 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 Within one hour
Chamberlain 1997 4/13 4/11 100.0 % 0.85 [ 0.27, 2.62 ]
Subtotal (95% CI) 13 11 100.0 % 0.85 [ 0.27, 2.62 ]
Total events: 4 (Midazolam), 4 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
0.01 0.1 1 10 100
Favours Midazolam Favours Diazepam
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Analysis 10.1. Comparison 10 Intramuscular midazolam versus rectal diazepam, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 10 Intramuscular midazolam versus rectal diazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Within 1 hour
Momen 2015 48/50 47/50 100.0 % 1.02 [ 0.93, 1.12 ]
Subtotal (95% CI) 50 50 100.0 % 1.02 [ 0.93, 1.12 ]
Total events: 48 (Midazolam), 47 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
0.5 0.7 1 1.5 2
Favours Diazepam Favours Midazolam
Analysis 11.1. Comparison 11 Intravenous midazolam versus intravenous diazepam, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 11 Intravenous midazolam versus intravenous diazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 39/40 36/40 100.0 % 1.08 [ 0.97, 1.21 ]
Total (95% CI) 40 40 100.0 % 1.08 [ 0.97, 1.21 ]
Total events: 39 (Midazolam), 36 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Diazepam Favours Midazolam
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Analysis 11.2. Comparison 11 Intravenous midazolam versus intravenous diazepam, Outcome 2 Time from
drug administration to stopping of seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 11 Intravenous midazolam versus intravenous diazepam
Outcome: 2 Time from drug administration to stopping of seizures
Study or subgroup Midazolam Diazepam
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Seconds] N Mean(SD)[Seconds] IV,Fixed,95% CI IV,Fixed,95% CI
Gathwala 2012 40 92.62 (25.97) 40 84.94 (38.56) 100.0 % 7.68 [ -6.73, 22.09 ]
Total (95% CI) 40 40 100.0 % 7.68 [ -6.73, 22.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours Midazolam Favours Diazepam
Analysis 11.3. Comparison 11 Intravenous midazolam versus intravenous diazepam, Outcome 3 Incidence
of respiratory depression.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 11 Intravenous midazolam versus intravenous diazepam
Outcome: 3 Incidence of respiratory depression
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 0/40 1/40 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 40 40 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (Midazolam), 1 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Midazolam Favours Diazepam
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Analysis 11.4. Comparison 11 Intravenous midazolam versus intravenous diazepam, Outcome 4 Additional
dose of the trial drug required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 11 Intravenous midazolam versus intravenous diazepam
Outcome: 4 Additional dose of the trial drug required to stop seizures
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 1/40 4/40 100.0 % 0.25 [ 0.03, 2.14 ]
Total (95% CI) 40 40 100.0 % 0.25 [ 0.03, 2.14 ]
Total events: 1 (Midazolam), 4 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midazolam Favours Diazepam
Analysis 11.5. Comparison 11 Intravenous midazolam versus intravenous diazepam, Outcome 5 Seizure
recurrence within 24 hours.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 11 Intravenous midazolam versus intravenous diazepam
Outcome: 5 Seizure recurrence within 24 hours
Study or subgroup Midazolam Diazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 2/40 4/40 100.0 % 0.50 [ 0.10, 2.58 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.10, 2.58 ]
Total events: 2 (Midazolam), 4 (Diazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midazolam Favours Diazepam
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Analysis 12.1. Comparison 12 Intravenous midazolam versus intravenous lorazepam, Outcome 1 Seizure
cessation.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 12 Intravenous midazolam versus intravenous lorazepam
Outcome: 1 Seizure cessation
Study or subgroup Midazolam Lorazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 39/40 40/40 100.0 % 0.98 [ 0.91, 1.04 ]
Total (95% CI) 40 40 100.0 % 0.98 [ 0.91, 1.04 ]
Total events: 39 (Midazolam), 40 (Lorazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Lorazepam Favours Midazolam
Analysis 12.2. Comparison 12 Intravenous midazolam versus intravenous lorazepam, Outcome 2 Time
from drug administration to stopping of seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 12 Intravenous midazolam versus intravenous lorazepam
Outcome: 2 Time from drug administration to stopping of seizures
Study or subgroup Midazolam Lorazepam
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Seconds] N Mean(SD)[Seconds] IV,Fixed,95% CI IV,Fixed,95% CI
Gathwala 2012 40 92.62 (25.97) 40 91.12 (23.58) 100.0 % 1.50 [ -9.37, 12.37 ]
Total (95% CI) 40 40 100.0 % 1.50 [ -9.37, 12.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Midazolam Favours Lorazepam
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Analysis 12.3. Comparison 12 Intravenous midazolam versus intravenous lorazepam, Outcome 3
Additional dose of the trial drug required to stop seizures.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 12 Intravenous midazolam versus intravenous lorazepam
Outcome: 3 Additional dose of the trial drug required to stop seizures
Study or subgroup Midazolam Lorazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 1/40 0/40 100.0 % 3.00 [ 0.13, 71.51 ]
Total (95% CI) 40 40 100.0 % 3.00 [ 0.13, 71.51 ]
Total events: 1 (Midazolam), 0 (Lorazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midazolam Favours Lorazepam
Analysis 12.4. Comparison 12 Intravenous midazolam versus intravenous lorazepam, Outcome 4 Seizure
recurrence within 24 hours.
Review: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
Comparison: 12 Intravenous midazolam versus intravenous lorazepam
Outcome: 4 Seizure recurrence within 24 hours
Study or subgroup Midazolam Lorazepam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gathwala 2012 2/40 2/40 100.0 % 1.00 [ 0.15, 6.76 ]
Total (95% CI) 40 40 100.0 % 1.00 [ 0.15, 6.76 ]
Total events: 2 (Midazolam), 2 (Lorazepam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Midazolam Favours Lorazepam
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A D D I T I O N A L T A B L E S
Table 1. Event rates for seizure cessation, respiratory depression and additional drugs required
Study Drug Seizure cessation Respiratory Depression Additional drugs required
No. of
Events
No. of
Children
% No. of
Events
No. of
Children
% No. of
Events
No. of
Children
%
Ahmad
2006
IN lo-
razepam
60 80 75 0 80 0 8 80 10
IM par-
aldehyde
49 80 60 0 80 0 21 80 26
Appleton
1995
IV lo-
razepam
19 27 70 1 27 4 1 27 4
Rectal lo-
razepam
6 6 100 0 6 0 0 6 0
IV
diazepam
22 34 65 7 34 21 5 34 15
Rectal di-
azepam
6 19 32 1 19 5 12 19 63
Arya
2011*
IN lo-
razepam
16 23 70 1 71 1 NR 23 NA
IV lo-
razepam
26 35 74 2 70 3 NR 35 NA
Ashrafi
2010
Buc-
cal mida-
zolam
49 49 100 0 49 0 0 49 0
Rectal di-
azepam
40 49 82 0 49 0 9 49 18
Baysun
2005
Buc-
cal mida-
zolam
18 23 78 0 23 0 5 23 22
Rectal di-
azepam
17 20 85 1 20 5 3 20 15
Cham-
berlain
1997
IM mida-
zolam
12 13 92 0 13 0 1 13 8
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Table 1. Event rates for seizure cessation, respiratory depression and additional drugs required (Continued)
IV
diazepam
10 11 91 0 11 0 1 11 9
Cham-
berlain
2014
IV
diazepam
101 140 72 26 140 16 21 140 15
IV lo-
razepam
97 133 73 26 133 18 21 133 16
Fi gin
2002
IN mida-
zolam
20 23 87 0 23 0 3 23 13
Rectal di-
azepam
13 22 60 0 22 0 9 22 40
Gath-
wala
2012
IV
diazepam
36 40 90 1 40 3 4 40 10
IV mida-
zolam
39 40 98 0 40 0 1 40 3
IV lo-
razepam
40 40 100 0 40 0 0 40 0
Javadzadeh
2012
IN mida-
zolam
NR 30 NA NR 30 NA NR 30 NA
IV
diazepam
NR 30 NA NR 30 NA NR 30 NA
Lahat
2000
IN mida-
zolam
23 26 88 0 26 0 NR 26 NA
IV
diazepam
24 26 92 0 26 0 NR 26 NA
Mah-
moudian
2004
IN mida-
zolam
35 35 100 0 35 0 0 35 0
IV
diazepam
35 35 100 0 35 0 0 35 0
McIntyre
2005
Buc-
cal mida-
zolam
61 109 56 5 109 5 36 109 33
Rectal di-
azepam
30 110 27 7 110 6 63 110 57
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Table 1. Event rates for seizure cessation, respiratory depression and additional drugs required (Continued)
Momen
2015
IM mida-
zolam
48 50 96 1 50 2 NR 50 NA
Rectal di-
azepam
47 50 94 0 50 0 NR 50 NA
Mpim-
baza
2008
Buc-
cal mida-
zolam
125 165 76 2 165 1 NR 165 NA
Rectal di-
azepam
114 165 69 2 165 1 NR 165 NA
Shah
2005
IM mida-
zolam
45 50 90 0 50 0 5 50 10
IV
diazepam
29 31 90 0 31 0 2 31 6
Sreenath
2010
IV lo-
razepam
90 90 100 4 90 4 6 90 7
IV
diazepam
with
pheny-
toin
88 88 100 5 88 6 14 88 16
Talukdar
2009
Buc-
cal mida-
zolam
51 60 85 0 60 0 9 60 15
IV
diazepam
56 60 93 0 60 0 4 60 7
Abbreviations: IM: Intramuscular; IN: Intranasal; IV: Intravenous; NR: Not reported; NA: Not available (percentages could not be
calculated where event rate was NR)
*Occurences of respiratory depression were not reported for the subgroup of participants with generalised tonic-clonic seizures in Arya
2011, therefore these results refer to all participants (including 83 participants without generalised tonic-clonic seizures).
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A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialised Register search strategy
#1 MeSH DESCRIPTOR Child Explode All
#2 MeSH DESCRIPTOR Infant Explode All
#3 paediatr* or pediatr* or child* or infant*
#4 #1 OR #2 OR #3
#5 emergency or emergencies or acute
#6 #4 AND #5
#7 >17/10/2013:CRSCREATED
#8 #6 AND #7
Appendix 2. CENTRAL via CRSO search strategy
#1 MESH DESCRIPTOR Epilepsy, Tonic-Clonic EXPLODE ALL TREES
#2 (tonic ADJ2 clonic):TI,AB,KY
#3 MESH DESCRIPTOR Status Epilepticus EXPLODE ALL TREES
#4 (status ADJ2 epilepti*):TI,AB,KY
#5 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#6 (epilep* and (seizure* or convuls*)):TI,AB,KY
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 MESH DESCRIPTOR Pediatric Emergency Medicine EXPLODE ALL TREES
#9 MESH DESCRIPTOR Child EXPLODE ALL TREES
#10 MESH DESCRIPTOR Infant EXPLODE ALL TREES
#11 (paediatr* or pediatr* or child* or infant*):TI,AB,KY
#12 #9 OR #10 OR #11
#13 (emergency or emergencies or acute):TI,AB,KY
#14 #12 AND #13
#15 #8 OR #14
#16 #7 AND #15
#17 * NOT INMEDLINE AND 30/09/2013 TO 30/06/2017:DL
#18 #16 AND #17
Appendix 3. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. exp Epilepsy, Tonic-Clonic/
2. (tonic adj2 clonic).tw.
3. exp Status Epilepticus/
4. (status adj2 epilepti$).tw.
5. exp Seizures/
6. (epilep$ and (seizure$ or convuls$)).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Pediatric Emergency Medicine/
9. exp child/ or exp infant/
10. (paediatr$ or pediatr$ or child$ or infant$).tw.
11. 9 or 10
12. (emergency or emergencies or acute).tw.
13. 11 and 12
14. 8 or 13
15. 7 and 14
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16. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
17. clinical trials as topic.sh.
18. trial.ti.
19. exp Random Allocation/
20. exp Double-Blind Method/
21. exp Single-Blind Method/
22. exp Clinical Trial/
23. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
24. (clin$ adj2 (study or studies or trial?)).tw.
25. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
26. (control$ adj2 (study or studies or trial?)).tw.
27. exp cross-over studies/
28. (cross?over adj2 (analy$ or method or procedure or study or studies or trial?)).tw.
29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. (animals not human).sh.
31. 29 not 30
32. 15 and 31
33. remove duplicates from 32
34. limit 33 to ed=20131017-20170523
35. 33 not (1$ or 2$).ed.
36. 35 and (2013$ or 2014$ or 2015$ or 2016$ or 2017$).dc.
37. 34 or 36
Appendix 4. ClinicalTrials.gov search strategy
acute OR emergency OR emergencies | tonic-clonic convulsions OR status epilepticus | drug | Child
Appendix 5. ICTRP search strategy
Condition: tonic-clonic convulsions OR status epilepticus
Intervention: drug
Clinical trials in children
Recruitment status: all
WH A T ’ S N E W
Last assessed as up-to-date: 23 May 2017.
Date Event Description
23 May 2017 New search has been performed Searches updated 23 May 2017.
23 May 2017 New citation required and conclusions have changed We have added 14 new studies in this update. The authors’
conclusions have changed to suggest that buccal midazolam
is more effective than rectal diazepam, with a very low risk
of adverse events. Intravenous benzodiazepines lead to more
rapid seizure cessation but time taken to establish IV access
undermines this effect. The findings of the previous review
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(Continued)
(intravenous lorazepam is at least as effective as intravenous
diazepam and is associated with fewer adverse events) are
supported by this update
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 4, 2002
Date Event Description
21 October 2008 Amended Search strategy amended to comply with RevMan 5 for-
mat.
8 May 2008 New search has been performed We re-ran our searches on 1st July 2007 and found three
new studies (Ahmad 2006;Lahat 2000; McIntyre 2005)
with 381 participants so there are now four included
studies with a total of 483 participants - all hospital based
7 May 2008 New citation required and conclusions have changed Substantive amendment
7 May 2008 Amended Converted to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol was published in 2000 (Appleton 2000), and the review was last updated in 2008 (Appleton 2008). Therefore changes
have been made to the format and content of the methods and the review from the protocol and from the last update to this version
of the review, in line with current MECIR standards (MECIR 2012) and the Cochrane Style Manual.
The original protocol specified that we would include non-randomised studies and adult studies (including adolescents between the
ages of 12 and 16), as we anticipated that we would find few randomised paediatric studies. The number of published studies in this
research field has greatly increased since publication of the protocol, so for this update we revised the inclusion criteria to cover only
randomised paediatric studies. These criteria were changed before we ran the updated searches and before starting the review update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Administration, Oral; Administration, Rectal; Anticonvulsants [administration & dosage; ∗therapeutic
use]; Diazepam [administration & dosage]; Epilepsy, Tonic-Clonic [∗drug therapy]; Injections, Intramuscular; Injections, Intravenous;
Lorazepam [administration & dosage]; Midazolam [administration & dosage]; Randomized Controlled Trials as Topic; Status Epilep-
ticus [∗drug therapy]
MeSH check words
Child; Humans
118Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
